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Abstract 
 
A STUDY OF ACOUSTICALLY ACTIVATED NANODROPLETS 
 
Songita Choudhury, Ph.D. 
University of Nebraska, 2018 
Supervisor: Thomas R. Porter, M.D. 
 Current treatment of acute myocardial infarction (AMI), which is the main 
pathophysiological event leading to death in the United States, has advanced considerably 
with the introduction of emergent percutaneous interventions, but there remains an urgent 
need for novel techniques to rapidly and accurately detect infarcted or ischemic tissue that 
results from AMI.  
 Ultrasound contrast agents, also known as microbubbles (MB), have become 
commonplace in echocardiography. However, MBs are purely intravascular tracers and 
unable to cross endothelial barriers due to size. The limitations of MBs, namely size and 
short circulation times within the human body, led to the development of phase-change 
agents (PCA) or nanodroplets (ND). The size and stability of NDs introduced potential for 
development of applications that extend into the extravascular space.   
In this dissertation, we presented a novel method for detection and quantification 
of the infarct zone after AMI through the delayed contrast enhancement of a PCA. The 
first study characterized the properties of a ND formed from a MB precursor before in vitro 
and in vivo experiments were performed to understand the acoustic behavior of the 
particle. The results from this study demonstrated that a significant population of NDs < 
250 nm in size could be formulated, and a commercial ultrasound system could be utilized 
to activate and visualize the PCA. The NDs also had significantly different acoustic 
behavior than their precursor.  
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We also investigated the viability of the NDs for diagnostic imaging in the setting 
of AMI. A rodent and porcine model of AMI were utilized to test the use of the NDs to 
selectively enhance the infarcted tissue within the myocardium. Through refinement of the 
ultrasound imaging protocol, selective enhancement of infarction zone was demonstrated. 
Both the MB precursor and the ultrasound system utilized in the studies are currently used 
in clinical cardiology, thus this methodology could be brought from the bench to bedside 
to rapidly diagnose myocardial infarction in the acute setting. 
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1.1 Heart Disease 
1.1.2 Burden of Heart Disease 
Heart disease (HD) remains the leading cause of death in the developed world 
(Benjamin et al. 2017; Yusuf et al. 2004; Lozano et al. 2012). In the United States, it is 
estimated that 92 million Americans are afflicted with at least one type of HD, and by 2030, 
it is projected that approximately 44% of American adults will have HD (Benjamin et al. 
2017). While there is an increase in the number of people developing HD, the death rates 
from 2004-2014 have decreased 6.7% though mortality was over 360,000 last year 
(Benjamin et al. 2017; Yusuf et al. 2004). Despite the declining death rate, the costs 
associated with this disease were estimated to be over $200 billion annually (Benjamin et 
al. 2017). Among the different types of HD, myocardial infarction and ischemia are the 
main pathophysiologic events that lead to death in the United States (Benjamin et al. 2017; 
Lozano et al. 2012).  
  
1.1.2 Myocardial Infarction 
In the United States, an American will have a myocardial infarction every 40 
seconds resulting in over 114,000 deaths per year. It is predicted that this year over 
695,000 patients will have a new coronary event, over 325,000 will have a recurrent event, 
and approximately 165,000 coronary events will go undetected (silent myocardial 
infarction) (Benjamin et al. 2017). 
 Acute myocardial infarction (AMI) most commonly occurs after a plaque ruptures 
leading to formation of a thrombus that obstructs blood flow within a coronary artery, which 
limits oxygenation of the local tissue (Mehta et al. 2016; Thygesen et al. 2012). AMI may 
also result due to plaque erosions or because of calcific nodules that lead to thrombus 
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formation (Mehta et al. 2016). During AMIs, three zones – infarct zone, border zone, and 
remote zone – are created. The area encompassing the injury site is known as the infarct 
zone; the tissue in this zone has been devoid of blood supply and becomes necrotic. The 
area just outside the infarct zone is known as the border zone, and this tissue has been 
afflicted by impaired blood flow. If medical interventions do not take place in a timely 
manner to recanalize the occluded artery, the border zone is at risk of becoming necrotic. 
The last zone, which is outside of the border zone, is an area that is unaffected by the 
changes in blood flow and least at risk of becoming injured.  
After injury to the tissue, cardiac repair occurs in two phases – the inflammatory 
phase, and the reparative and proliferative phase (Prabhu and Frangogiannis 2016). 
During the inflammatory phase, inflammation occurs and immune cells infiltrate the area 
to begin removing the damaged cells and surrounding extracellular matrix. Inflammation 
is needed to initiate the second phase of the repair process; however, it is also important 
that the inflammation end in a timely manner. Persistent inflammation may result in heavy 
fibrosis, scarring, tissue loss, or tissue dysfunction. As the inflammatory phase come to 
completion, the second phase begins where myofibroblasts are activated, scar forms, 
neovascularization occurs, and wound healing commences (Prabhu and Frangogiannis 
2016).  
To ensure that the pathophysiological consequences of AMI are minimized, it is 
vital to recognize the signs and symptoms of the disease and promptly take medical action. 
The most typical symptoms of AMI are chest pain or discomfort; however, women will 
often present with atypical symptoms, such as, pain in the arm or shoulder, fatigue, 
dyspnea, weakness, nausea, or indigestion (Mehta et al. 2016). After arriving at a medical 
center, standard treatment for AMI is percutaneous coronary intervention (PCI), which 
includes stenting and angioplasty (Suryapranata et al. 1998). However, in order to properly 
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treat patients who have undergone myocardial infarction, it is important to delineate the 
viable from the nonviable myocardium through imaging (Lardo et al. 2006; Mahnken et al. 
2005; Rischpler et al. 2015). According to the American Heart Association, it is 
recommended that PCI occurs within 90 minutes of the patient’s arrival to the medical 
facility in most cases; however, if PCI is not a viable option, medical therapy with 
fibrinolytics should be considered (O'Gara et al. 2013). Prompt treatment of this disease 
is imperative as patient outcomes are directly related to the severity of myocardial injury 
while the artery is occluded (Lardo et al. 2006). 
 The ultimate goal of any type of treatment for AMI is to rapidly recanalize the 
occluded coronary artery to limit myocardial infarct size without causing additional damage 
to the surrounding uninjured tissue (Prabhu and Frangogiannis 2016; Lardo et al. 2006). 
In most acute cases, rapid revascularization will result in improved heart function and 
patient outcomes; however, if revascularization is attempted in patients with little to no 
viable myocardium, the risk of mortality is increased (Lardo et al. 2006). Poor patient 
outcomes can also be attributed to delays in seeking and receiving medical care, 
underequipped medical facilities, and understaffed medical facilities (Benjamin et al. 
2017). There are ongoing efforts to develop new and refine current therapies to improve 
patient outcomes.   
 
1.2 Diagnostic Imaging of Myocardial Infarction 
1.2.1 Computed Tomography 
 Computed tomography (CT) is an imaging modality that utilizes several cross-
sectional X-rays to provide anatomic information. CT is commonly used in the emergency 
room to diagnose and assess non-cardiac events as well as evaluate patients who 
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complain of acute chest pain (Lardo et al. 2006; Pursnani et al. 2015). Though this 
modality is not utilized as a method to diagnose AMI, by computed tomography, infarcted 
myocardium appears as areas of reduced signal intensity (hypoenhancement) (Lardo et 
al. 2006). Perfusion imaging through CT gives the clinician information about both cardiac 
anatomy as wells as cardiac function and myocardial perfusion (Han et al. 2017).  
 CT imaging has better soft-tissue contrast as well as spatial resolution compared 
to echocardiography (Araoz et al. 1999). This imaging method also has reduced slice 
thickness making the spatial resolution in the z-axis better than magnetic resonance 
imaging (Lardo et al. 2006). CT also has several limitations including low contrast 
resolution and inability to provide real-time information (Hinzpeter et al. 2017). 
 
1.2.2 Magnetic Resonance Imaging 
 Magnetic resonance imaging (MRI) is a widely used imaging modality, especially 
for determining myocardial viability, due to its superior soft-tissue contrast and lack of 
radiation exposure (Lardo et al. 2006; Mahnken et al. 2005). MRI can provide some 
functional information (i.e. flow velocity and direction) on different imaging planes, 
however, real-time information is still unavailable (Araoz et al. 1999). 
 Although this is more cost-effective than other cardiac imaging modalities, 
myocardial infarction, in the chronic setting, may be detected through delayed 
enhancement MRI (DE-MRI); however, this method is not utilized to diagnose AMI (Kim 
et al. 1999; Lardo et al. 2006). DE-MRI requires the use of gadolinium, which accumulates 
in the regions of nonviable myocardium. However, the use of gadolinium also results in 
lengthened scan times (Lardo et al. 2006). On a T1 image, viable tissue appears dark, 
while injured or nonviable tissue has a higher signal intensity (Bremerich et al. 2000). 
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However, attempts to utilize MRI to evaluate the effectiveness of different therapies has 
been hampered by its inability to also assess the area at risk (Mahnken et al. 2005). The 
extent of T2 weighted assessments of edema by spin echo techniques has been shown 
to inaccurately quantify this measurement (Kim et al. 2015).   
MRI has several limitations and contraindications. Some of the contraindications 
include implanted defibrillators or pacers or other metal devices that may often be found 
in patients with heart disease (Lardo et al. 2006; Mahnken et al. 2005). This imaging mode 
is highly susceptible to motion artifacts that may be caused due heart and chest movement 
(Araoz et al. 1999). Lastly, the cost and availability of MRI worldwide limits its potential for 
being a diagnostic tool to detect high risk patients. 
 
1.2.3 Ultrasound Imaging 
 Ultrasound (US) is an increasingly utilized tool for diagnostic imaging as well as 
emerging therapeutic applications. Currently, it is commonly used in many areas of clinical 
medicine, and echocardiography is used regularly to identify cardiac abnormalities. US 
offers several advantages compared to other imaging modalities including: high portability, 
low-cost, no radiation, and real-time imaging (Zhang et al. 2015).  
 US utilizes sound waves that have frequencies higher than 20 kHz, and clinical 
diagnostic US systems typically operate between 1- 50 MHz (Coatney 2001). As the sound 
waves travel through the body, they encounter tissue of various densities, depth, and 
acoustic impedances. Acoustic impedance mismatches between tissues affect how the 
sound waves return to the US transducer; a higher mismatch will result in more sound 
waves, which will result in a brighter area on the image (Coatney 2001). US is ideal for 
soft tissue as sound does not travel well through air-filled structures and travels rapidly 
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through bone (Coatney 2001). The acoustic energy applied by sound waves is also called 
the mechanical index (MI), which is defined as the peak negative pressure (MPa) divided 
by the square root of the transducer’s center frequency (MHz). The United States Federal 
Drug Administration (FDA) restricts the range of MIs allowable on clinical US systems to 
minimize direct damage and avoid injury to the surrounding tissue (Barnett et al. 2000). 
 Echocardiography is utilized for wall motion analysis to detect acute myocardial 
ischemia or infarction. However, wall motion may appear normal when patients have had 
prior subendocardial infarction as it is difficult to detect ongoing or prior ischemia or prior 
infarction due to inadequate border delineation without the use of contrast enhancement. 
It also cannot differentiate chronic from acute infarctions. Furthermore, wall motion 
remains abnormal in both the risk area and infarct zone following ischemia reperfusion 
injury due to myocardial stunning, and thus, acute assessments of therapeutic 
effectiveness on myocardial salvageability cannot be made on the basis of wall motion 
analysis alone. Detection and quantification of both risk area and infarct size are critical in 
this clinical setting in order to determine both the efficacy of any given therapy and to 
determine patient prognosis. 
 
1.3 Microbubbles 
1.3.1 Development of Ultrasound Contrast Agents 
Microbubbles (MB) have been in use for several decades mainly as an ultrasound 
contrast agent (UCA) to improve diagnostic imaging (Figure 1). The first generation of MBs 
included substances such as hydrogen peroxide and agitated saline; they were quite 
unstable within the body and fairly large in size (Nanda 1997). As development of the 
second generation of UCAs began, the goal was to create particles with greater contrast,  
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Figure 1. Demonstration of echocardiography with UCA. The use of UCAs with US has 
increased the diagnostic power of echocardiography. UCAs provide improved 
opacification of the left ventricle and delineation of the endocardial borders. (A)-(D) 
demonstrate the change in US images in two views with the use of UCAs. (A) 4-chamber 
apical view prior to UCA; (B) 4-chamber apical view after UCA use; (C) apical long-axis 
view prior to UCA; and (D) apical long-axis view after UCA use.  
 
 
 
 
  
Before UCA After UCA 
A B 
C D 
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longer circulation times, and sizes small enough to pass through the pulmonary circulation. 
Echovist was one of the first commercial UCAs approved for use in Europe in the early 
1980s. In 1994, the FDA approved the first MB, Albunex, for clinical use (Sirsi and Borden 
2009). Since this time, there have been numerous MBs developed for commercial use in 
the United States and around the world. 
 
1.3.2 Microbubble Structure 
 Microbubbles are typically < 5 µm in diameter, which is smaller than the diameter 
of a red blood cell, allowing for unobstructed passage through vessels as small as 
capillaries (Lindner et al. 2002). While MBs are small enough to pass freely through the 
intravascular compartment, their size prevents they from moving through the gap junctions 
into the extravascular compartment – limiting their applications (Choudhury et al. 2017). 
Microbubbles are composed of a gaseous center that is encapsulated by a biodegradable 
shell that is composed of a lipid, protein, or polymer (Quaia 2007; Shekhar et al. 2018). 
Figure 2 depicts the structure of a MB. The shell acts as a stabilizer to maintain shape and 
size as the particles travel within the vasculature. To increase circulation time, most MBs 
now contain a fluorinated gas due to their low solubility in an aqueous environment 
(Kabalnov et al. 1998). It is due to this gaseous core that these particles produce 
backscatter enhancing the US image.  
 
 1.3.3 Current Microbubbles in Use 
 The most common UCAs in clinical use include, Optison (GE Healthcare, 
Princeton, NJ), Luminity/Definity (Lantheus Medical Imaging, Billerica, MA), and 
Lumason/Sonovue (Bracco Imaging S.p.A, Milan, Italy) (Claudon et al. 2013). The FDA  
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Figure 2. Definity microbubble structure. Definity MBs are typically ~1-3 µm in diameter. 
They have a lipid shell that encapsulates a octafluoropropane gaseous center. Other MBs 
have a shells that may be composed of protein, polymers, or albumin, and a gaseous 
center of perfluoropropane or sulfur hexafluoride. 
  
Gas 
Lipid 
Outer Shell 
~1 – 3 µm 
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has approved these particles for left ventricular opacification and endocardial border 
detection (Shekhar et al. 2018). Microbubbles have a few contraindications for clinical use, 
which include an unstable clinical condition, an allergy, or a sizeable right-to-left shunt 
(Schinkel, Kaspar, and Staub 2016). Table 1 describes a few examples of the current MBs 
in clinical use as well as their properties.  
 
1.3.4 Microbubble Behavior 
 When MBs are introduced into a liquid medium, the number of cavitation nuclei 
increases resulting in a reduction of the cavitation threshold (Liao et al. 2014). When US 
is applied to a MB, cavitation occurs causing the MB to be compressed at the peak positive 
pressure and expanded at the peak negative pressure (Figure 3) (Church and Carstensen 
2001). There are two types of cavitation – stable and inertial (Karshafian et al. 2009; Qin, 
Caskey, and Ferrara 2009). The application of ultrasound will result in different MB effects 
depending on the acoustic pressure applied as shown in Figure 3.  
 Stable cavitation occurs when low acoustic pressures are applied to the particles. 
In this state, the MB will expand and contract causing more reflection back to the US 
probe, creating a more brilliant US image (Qin, Caskey, and Ferrara 2009). As the particles 
oscillate, they cause streaming within the fluid resulting in mixing of materials in the vicinity 
of the MB (Ohl et al. 2006). At the low pressures, a radiation force may also be caused, 
which pushes particles away from the source of acoustic energy. Microbubbles resonate 
at frequencies within the range of frequency of most clinical US systems though stable 
cavitation will also cause the MBs to produce nonlinear scattering of the US signal (Sirsi 
and Borden 2009).  
When higher acoustic pressures are applied to MBs, they exhibit significantly  
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Table 1. Examples of the current microbubbles in clinical use.  
Microbubble Shell Coating Gas Mean Size (µm) Manufacturer 
Place(s) 
Approved 
Sonovue/ 
Lumason Phospholipid 
Sulfur 
hexafluoride 1.5 – 2.5 
Bracco 
Imaging S.p.A. Europe, US 
Optison Human Serum Albumin Octafluoropropane 3.0 – 4.5 GE Healthcare US, Europe 
Definity Phospholipid Octafluoropropane 1.1 – 3.3 Lantheus Medical 
US, 
Canada 
Sonazoid Phosphatidylserine Perfluorobutane 2.0 – 3.0 Daiichi-Sankyo Japan 
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Figure 3. Microbubble behavior with ultrasound. With the application of US, MBs will 
expand at peak negative pressure and compress at peak positive pressure. At low 
acoustic energies, the MBs will continue in a steady state of expansion and compression. 
However, at very high pressures, the MBs can become unstable and erupt. 
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different behavior. The particles will oscillate nonlinearly producing a harmonic signal (Ma 
et al. 2015). Dissolution of the particles will occur at pressures slightly below peak negative 
pressures (Chomas et al. 2001). As pressures approach peak negative pressure, 
oscillations become more unstable eventually leading to rapid expansion of the particle 
followed by a violent eruption, a state known as inertial cavitation (Qin, Caskey, and 
Ferrara 2009; Stride 2009). As the MB erupts, it sends shockwaves through the local 
environment (Roos et al. 2014). The MB behavior and its effects on the local environment 
have greatly broadened the applications of these particles within a physiological system 
(Liao et al. 2014). Figure 4 demonstrates a few MB behaviors due to stable or inertial 
cavitation.  
   
1.3.5 Brief Description of Applications 
UCAs were initially developed for enhancing diagnostic applications. In Canada 
and Europe, UCAs are used during echocardiography and radiology (Piscaglia et al. 2012; 
Piscaglia et al. 2017). In the United States, the FDA approved MBs for left ventricular 
opacification and improved endocardial border detection before recently expanding their 
use to image focal liver lesions as well (Shekhar et al. 2018). 
For diagnostic imaging, the MI must be kept fairly low to prevent destruction of the 
particle. Continuous imaging can be performed while the MI is maintained between 0.1 
and 0.3, and triggered imaging can be performed from 0.3 to 0.5 MI (Porter et al. 2014). 
When imaging the heart, MBs provide stark contrast between the blood-tissue boundary, 
which greatly increases diagnostic power in determining wall motion abnormalities, 
thrombus detection, as well as ejection fraction estimation (Qin, Caskey, and Ferrara 
2009). While these UCAs have primarily been approved for cardiac applications, clinicians 
    
 
15 
 
Figure 4. Microbubble behavior in different cavitation states. While in the stable cavitation 
state, MBs may undergo several behaviors including microstreaming, expansion and 
radiation force. In the inertial cavitation state, MBs undergo more violent behavior, such 
as micro jets and shock wave, that may affect the surrounding cells.  
Stable Inertial 
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have used them to image various organs, determine perfusion in the myocardium and 
renal system, detect plaques and stenoses, locate thrombi, and determine vascularization 
of tumors. 
Over the past few decades, the physical properties of UCAs have slowly been 
dissected leading to a tremendous increase in development of therapeutic applications. 
Many of these applications require high acoustic energies, inertial cavitation, or a 
combination of stable and inertial cavitation. The therapeutic applications take advantage 
of the fact that MBs can be destroyed easily, especially while applying US in real-time. 
One common off-label use of MBs is for perfusion analysis. When myocardial 
perfusion is assessed, low MI real-time imaging is performed while the MBs are 
continuously infused. As contrast concentration reaches a steady-state within the imaging 
field, a background contrast level can be established. A high acoustic energy flash (a few 
pulses) is applied to destroy the MBs in the field, and perfusion can be determined by 
observing the rate of refill of the microcirculation (Becher and Burns 2000). 
The applications described next are often labeled theranostic. Several commercial 
US transducers now have the capability of performing as a diagnostic and therapeutic 
probe. This characteristic has eased the development of treatment modalities due to 
targeted activation of the contrast agent, which allows more control in tissue specific 
treatments (Chertok and Langer 2018).  
One of the fastest growing applications is the use of MBs for delivery – be it drugs, 
genes, proteins, oxygen etc. To improve the efficiency of delivery, ultrasound-targeted 
microbubble destruction (UTMD) is used. UTMD has a two-pronged effect: first, 
destruction of the MBs with high acoustic energy creates transient pores in the 
surrounding tissue, and second, these pores increase transport of particles across the cell 
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membrane (Cui et al. 2017). To facilitate delivery, the materials to be delivered can be co-
administered with the MBs, incorporated within the MBs, or attached to the shell of the 
MBs. This application has been a growing area of interest as a method of delivering 
chemotherapeutic drugs directly into tumors, which often have quite leaky vasculature. 
The US probe can first be used to obtain an enhanced image (low MI) of the tumor before 
the acoustic energy (high MI) is increased, causing MB destruction and targeted release 
of the drugs. A similar method can be used to deliver genetic materials. In many cases, 
cationic MBs are used to bind DNA or RNA to the surface to increase delivery (Xie et al. 
2012). MBs serve as a safer vessel for gene delivery compared to previous methods that 
have utilized viral vectors (Bez et al. 2017). The loading capacity of MBs is low, thus, these 
applications fair best when low volumes of drugs or genes are needed for optimum 
physiological activity. 
 Sonothrombolysis combines therapeutic US (inertial cavitation) and, typically, a 
fibrinolytic agent to dissolve a thrombus (Behrens et al. 2001). Thus, when MBs are 
combined with high MI US for sonothrombolysis, cavitation occurs within and around the 
thrombus (Petit et al. 2015), which causes destabilization of the structure (Schleicher et 
al. 2016). If a fibrinolytic agent, such as tissue plasminogen activator, is combined with 
MBs and US, it has been suggested that this allows better access to the fibrin strands, 
thus improving fibrin degradation and thrombus dissolution (Petit et al. 2015). While 
fibrinolytic treatment comes with a risk of bleeding, the use of US and MBs may allow for 
a lower dose of tissue plasminogen activator to achieve similar results and lowering 
hemorrhage risk. A few large animal studies have demonstrated the use of transcranial 
US and MBs to dissolve clots in the setting of ischemic stroke; subsequent studies have 
used this technique in combination with fibrinolytic agents in human patients with acute 
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ischemic stroke (Gao et al. 2014; Culp et al. 2011; Molina et al. 2009). While clinical trials 
have not been complete in patients with stroke, there are currently ongoing clinical trials 
in the Netherlands and Brazil studying the viability of treating myocardial infarction with 
sonothrombolysis (Mathias et al. 2016).  
 
1.4 Nanodroplets 
1.4.1 Development of Phase-Change Agents 
Microbubbles have several limitations including: particle size, which limits the 
particles to the intravascular compartment; stability after venous administration; and 
susceptibility to high acoustic energies, which limits resolution and applications (Porter et 
al. 2016; Blum et al. 2017). These limitations have led to development of many new 
contrast agents, and phase-change agents (PCAs) addressed several of these limitations.  
Phase-change agents, also known as nanodroplets (ND), are nanometer sized (50 
– 1000 nm) particles with liquid perfluorocarbon centers (Choudhury et al. 2017). The 
reduction in size introduces a means of reaching the extravascular compartment opening 
up a world of possible applications. Nanodroplets have greater stability in systemic 
circulation, and they can be formulated in a variety of sizes (Sheeran and Dayton 2014; 
Rojas and Dayton 2017).  
 
1.4.2 Phase-Change Agent Properties 
 PCAs can be formed through several processes (sonication, microfluidics, 
extrusion etc.); however, the most clinically-relevant process is a condensation process 
using MB precursors (Figure 5) (Sheeran, Luois, et al. 2011). Formulating NDs through  
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Figure 5. Formulation of phase-change agent. PCAs can be created by cooling and 
pressurization of a MB precursor also known as the condensation stage. In the ND state, 
the gaseous center has become a liquid, the Laplace pressure has increased, and the 
size of the particle has decreased. Prior to visualization by US, the NDs must return to the 
MB state. ND can be vaporized (activated) through the application of acoustic energy and 
the addition of heat resulting in the return to the MB state. This figure was adapted from 
Sheeran et al. (2012).    
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condensation of MBs allows for control of size and composition by careful selection of the 
MBs (Sheeran et al. 2013). Perfluorocarbon core MBs can be cooled and pressurized to 
form NDs. During this process, the gaseous core becomes a liquid and the size of the 
particle is greatly reduced. These particles are unique as the liquid perfluorocarbons 
remain in this state well above their boiling point due the increasing Laplace pressures as 
the particles get smaller.  
In this ND state, the particles remain invisible to US transducers at low MIs. Once 
the threshold MI is surpassed, the NDs will undergo acoustic droplet vaporization (ADV) 
– converting the ND to a MB with a gaseous core (Marshalek et al. 2016; Kripfgans et al. 
2000). The acoustic energy required to achieve vaporization is dependent on several 
factors, such as particle size (increasing Laplace pressure as size decreases), frequency 
of signal, composition of the encapsulating shell, and boiling point of the perfluorocarbon  
(Sheeran, Luois, et al. 2011; Mountford, Thomas, and Borden 2015). As the NDs vaporize, 
they will become 4 to 9 times their original size and visible by US. 
 Currently, the FDA allows MIs up to 1.9 for clinical applications, and since PCAs 
are not yet approved for clinical use, there is not a specified range of MIs (Marshalek et 
al. 2016). Large animal studies have shown that imaging with PCAs does not cause any 
harmful effects when the frequencies and MIs are carefully monitored (Marshalek et al. 
2016). Thus, creating PCAs ideal for clinical applications is a careful balance of gas and 
particle size, as these factors will determine the acoustic energy necessary for 
vaporization (Sheeran et al. 2013). As the boiling point of the perfluorocarbon increases, 
the threshold for vaporization also increases (Marshalek et al. 2016). It has also been 
demonstrated that low boiling point perfluorocarbons are ideal to limit unwanted damage 
or injury to local tissue when the NDs are vaporized (Lin et al. 2017).  
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Octafluoropropane and decafluorobutane show promise as good ND cores 
because the MI needed for ADV may be within the FDA approved range (Sheeran, Luois, 
et al. 2011; Sheeran, Wong, et al. 2011). It has been recently demonstrated by Porter et 
al. (2016) that octafluoropropane NDs can be vaporized using MIs that are allowable with 
clinical US systems within a large animal model. The activated NDs could be observed 
under high MI conditions in real-time, and the reactivated MBs appear to be more resistant 
to destruction at high MIs (Porter et al. 2016). 
 
1.4.3 Brief Description of Diagnostic and Therapeutic Applications 
 Many of the proposed applications for PCAs are similar to the current on- and off-
label uses of MBs. The main distinguishing characteristic of PCAs is the size of these 
particles, which has led to development of applications within the extravascular 
compartment or areas where MBs have not been able to reach. Some of the proposed 
uses for the NDs include tumor vascular imaging, vascular occlusion, drug and gene 
delivery, and high-intensity focused ultrasound (HIFU) therapy (Sheeran, Luois, et al. 
2011; de Gracia Lux et al. 2017). However, the potential for diagnostic and therapeutic 
applications of NDs is unknown.  
 Imaging with PCAs is an application that has been the least explored. There are 
several advantages to using these particles for imaging: their small size may allow 
passage across leaky endothelium to image areas that cannot be imaged with MBs; they 
have increased stability at physiological temperatures; and, due to the high threshold of 
activation, targeted imaging is possible (Sheeran et al. 2013; Wu et al. 2017). Imaging 
with NDs is more challenging than other UCAs due to the high MI required for ADV, which 
requires the US transducer to be capable of both activation and imaging. Despite this 
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challenge, Sheeran et al. have demonstrated the use of a low boiling point perfluorocarbon 
PCA for molecular imaging with activation from a clinical diagnostic US system (Sheeran 
et al. 2013). Molecular imaging has also been widely used for imaging tumors and 
determining their phenotype (Rapoport et al. 2010). Marshalek et al. have complete 
feasibility in vitro studies showing folate-targeted delivery and activation of PCAs in breast 
cancer cells (Marshalek et al. 2016). Molecular imaging with PCAs has yet to reach the 
clinic. 
 The vast majority of PCA uses have been focused on the development of 
therapeutic applications. Gene and drug delivery has become of interest due to the 
possibility of extravasation (Fix et al. 2017). The capability of formulating NDs from 
precursor MBs allows for loading the surface or interior of MBs with drugs or genetic 
material prior to condensation (Sheeran et al. 2013). One particular area of interest is 
delivery to the brain. Previous studies have shown the use of MBs to increase permeability 
of the blood-brain barrier. Recent studies have demonstrated that the use of PCAs to open 
the blood-brain barrier results in less damage to the surrounding cells due to the high 
threshold to activating the NDs resulting in fewer MBs created (Chen et al. 2013). Wu et 
al. were able to utilize octafluoropropane NDs to, first, open the blood-brain barrier and 
then deliver large particles into the brain in a murine model; US activation of the NDs did 
not cause negative bioeffects to the surrounding tissue (Wu et al. 2017). This study 
demonstrated the possibility of delivering large drug molecules or genetic material into the 
brain through the use of a low boiling point perfluorocarbon PCA. A similar method of 
delivery has also been tested in several types of tumors. The PCAs are allowed to 
extravasate into the tumor before high MI US is applied to the area causing the ND to 
vaporize, and, with further application of US, the MBs will cavitate releasing the contents 
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locally (Rapoport et al. 2010). These studies have been performed on animal models and 
have not yet reached clinical medicine. 
 Another area of interest is the use of PCAs for HIFU ablation. HIFU is currently 
used clinically to treat numerous solid tumors, uterine fibroids, and bone metastases 
(Moyer et al. 2015; Kopechek et al. 2014). This technique is used to ablate tissue by 
applying US to create focal increases in temperature leading to necrosis of the tissue (Liu 
et al. 2006). Some safety concerns with this technique include damage to the skin and the 
length of treatment time (Moyer et al. 2015). HIFU in combination with MBs has been 
studied as a method to improve ablation of the tumors, however, they focus heating 
around vessels and do not circulate for long (Kopechek et al. 2014). The use of NDs could 
result in extravasation of the particles and enhanced localized heating (Zhang and Porter 
2010). Since NDs require a high acoustic energy to be activated, HIFU will cause heating 
at the US focus and will leave the surrounding tissue relatively unharmed (Moyer et al. 
2015). This technique has been demonstrated recently in a rabbit tumor model suggesting 
that this could lead to reduction in treatment time and acoustic energies required to treat 
solid tumors (Kopechek et al. 2014).   
 
1.5 Thesis Outline 
In this thesis, we examined the properties of an acoustically activated ND and 
sought to determine whether the NDs have the capability to be utilized as an extravascular 
contrast agent in the setting of AMI. In the upcoming chapters, the ND properties were 
characterized before their use as an extravascular agent in animal models of AMI was 
studied. 
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The first objective was to establish a method of ND formulation, and the second 
objective was to determine the acoustic behavior of the NDs. In Chapter 2, the creation of 
NDs though condensation of a commercially-available MB precursor is described. Definity 
MBs were chosen as the precursor due to its octafluoropropane gaseous center. Various 
pressure and temperature settings were utilized to assess their effects on size of NDs 
formulated. Next, an in vitro flow system mimicking transthoracic US imaging was used to 
determine if the NDs could be activated (vaporized) using a clinical US system. 
Subsequently, the in vitro flow system was utilized to study the acoustic behavior of the 
NDs as the MI and frequency of imaging was altered. In vivo activation and acoustic 
behavior of the NDs was also tested in healthy swine to determine the feasibility of use of 
these particles in a physiological system. 
The results from the initial study suggested that that the formulated NDs had the 
potential for use as an extravascular contrast agent. The third objective was to determine 
if the NDs were able to extravasate in order to be used to enhance myocardial infarct 
imaging. Finally, the fourth objective was to scale the imaging protocol into a large animal 
model. Chapter 3 first describes the use of a rodent model of AMI to assess the capability 
of the NDs to image the infarcted myocardial tissue. Extravasation of the NDs was 
examined through the use of fluorescently-tagged NDs that were administered to the rats 
without imaging. Fluorescent microscopy was used to determine if there was ND 
accumulation in the infarct zone. An US imaging protocol was developed to enhance the 
infarct zone. The promising results and limitations associated with the rodent model lead 
to testing of the NDs within an established porcine model of AMI. The porcine model was 
utilized to further modify the imaging scheme to selectively activate the NDs in the infarct 
zone. MRI was used as a method of comparison when determining the size and location 
of the infarcted myocardium.     
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Completion of these objectives demonstrates a methodology that could be brought 
from bench to the bedside to detect scar or even remote ischemia. A summary of the work 
described in this thesis as well as suggested future directions are presented in Chapter 4.  
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Chapter 2  
 
 
Acoustic behavior of a reactivated, commercially-
available ultrasound contrast agent 
 
 
The following is a modified version of:  
 
Choudhury SA, Xie F, Dayton PA, Porter TR. Acoustic behavior of a reactivated, 
commercially-available ultrasound contrast agent. JASE, 2017. 30(2): 189-197.  
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2.1 Introduction 
 
The use of MBs for contrast enhancement during diagnostic US imaging has 
become common over the past few decades (Reznik et al. 2014). Microbubbles have been 
used as a contrast agent in a wide variety of medical applications, including solid-organ 
tumor detection and enhanced cardiac imaging (Reznik et al. 2014; Li et al. 2015). Current 
United States Food and Drug Administration – approved MBs have also been used for off-
label applications such as free intravascular tracers for myocardial perfusion analysis 
(Porter 2009). Microbubbles are typically 1 to 5 µm in diameter and are composed of a 
gaseous center encapsulated by a protein, lipid, or polymer shell. This size prohibits 
crossing into extravascular spaces (Reznik et al. 2014; Arena et al. 2015). 
 Phase-change US contrast agents are nanometer-sized droplets, or NDs, that also 
contain fluorocarbons in their liquid form. These fluorocarbons stay in a liquid form well 
above their boiling points. Their size (50-1000 nm) results in increased Laplace pressure 
that prevents boiling and also increases the acoustic energy necessary to vaporize the 
NDs (Matsunaga et al. 2012). Because of this significant limitation, it has been difficult to 
formulate a PCA that is stable at physiologic temperature but can also be activated into 
stable MBs after vaporization (Matsunaga et al. 2012; Sheeran et al. 2015).  
 Recently, it has been shown that even perfluoropropane (the fluorocarbon gas that 
is used to formulate commercially-available contrast agents such as Definity) ('DEFINITY 
® [package insert]. Lantheus Medical Imaging, Inc., N. Billerica, MA.'  2017) can remain in 
liquid form at body temperature, even though its boiling point is -36.7°C (National Center 
for Biotechnology Information 2018). We have been able to condense Definity MBs 
(DMBs) into Definity NDs (DDs) using a modification of protocols published by Matsunaga 
et al. (2012) and Sheeran et al. (2015). Some investigators have shown the reactivated 
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MBs formed from lipid-encapsulated NDs may have different acoustic responses that 
affect their destruction rates and stability (Reznik et al. 2014; Shpak et al. 2014). A variety 
of potential explanations exist for the altered acoustic behavior of the reactivated MBs, 
including altered shell characteristics upon reactivation, larger size distribution, and more 
resistance to acoustic destruction (Reznik et al. 2014; Porter et al. 2016). We 
hypothesized that DDs could be reactivated using a technique observed with other 
perfluoropropane NDs (Porter et al. 2016). Furthermore, we postulated that their behavior 
in the presence of the US imaging protocols used for contrast imaging (real-time and 
triggered) would be different from DMBs because of the requirement that they first must 
be activated before being detected with imaging. In this study, we compared the acoustic 
responses of DDs with those of standard DMBs and the potential for specifically activating 
the < 220 nm NDs that may cross defective vascular endothelial barriers and be used for 
extravascular applications. 
 
2.2 Methods 
 
2.2.1 Microbubbles 
 
All experiments were conducted using commercially-available DMBs. The DMB 
vials were stored at 4 °C. To prepare the DMBs, a vial of the MBs was warmed to room 
temperature (25 °C) and mechanically agitated (Vialmix shakers, Bristol-Myers-Squibb, 
New York, NY) for approximately 45 seconds. According to the package insert, the 
diameters ranged from 1.1-3.3 µm, and the maximum concentration of the DMBs was 
1.2x1010 microspheres/mL ('Definity® (perflutren lipid microsphere) [package insert]. 
Lantheus Medical Imaging, N. Billerica, MA'  2018).  
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2.2.2 Creation of Nanodroplets 
 
The protocol to formulate the DDs was adapted from Sheeran et al. (Sheeran et 
al. 2015) and Matsunaga et al. (Matsunaga et al. 2012). To create the DDs, 2 mL vials of 
DMBs were agitated for 45 seconds using a Vialmix; next, 0.9% saline was used to create 
a 1% solution of DMBs; the DMB solution was then placed in a 70% isopropyl alcohol bath 
at a temperature between -10 ºC and -15 ºC for approximately three minutes; manual 
pressure was applied for approximately three minutes until the solution became 
translucent (Figure 6), which indicated that condensation of the particles had occurred. 
Prior to experimentation, the solutions were warmed to room temperature (25 °C). To 
investigate the properties of a subset of the DDs, a 10% solution of DDs was passed 
through a 220 nm filter (Merck Millipore, Billerica, MA). 
 
2.2.3 Microbubble and Nanodroplet Sizing   
 
The DDs were found to have polydisperse distribution after condensation (Shpak 
et al. 2014). The DDs were sized using two different devices: a Nano Zetasizer (Malvern 
Nano ZS, Malvern Instruments Ltd., Malvern, Worcestershire, U.K.), which can measure 
particles up to 10 µm diameter; and a NanoSight NS300 (Malvern NanoSight, Malvern 
Instruments Ltd., Malvern, Worcestershire, U.K.), which is capable of sizing particles as 
small as 10 nm in diameter. Initially, the Nano Zetasizer was used to size the filtered and 
unfiltered DDs (n = 3 each) to verify that that the larger NDs were appropriately removed 
from the solutions. Next, the filtered DD solutions (n = 6) were sized using the NanoSight 
NS300 to improve resolution of the NDs with diameters < 1 µm, and to determine how the 
diameter of the filtered DDs changed over a 24-hour period while at 25 ºC. The DMB 
solution (n = 3) was analyzed with the Nano Zetasizer to determine the full range of sizes   
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Figure 6. Nanodroplet Formulation. Cooling and pressurization of DMBs (left panel) results 
in the creation of DDs (right panel). The change in state from MBs to NDs is confirmed 
with a visual change in opacity – MB solutions are opaque and ND solutions are 
translucent.   
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produced with mechanical agitation. The sizes produced with manual pressure were 
compared with those produced with known applied pressure of 6, 9, and 12 atm using a 
high-pressure inflation device for angioplasty balloon catheters (Merit Medical Systems, 
Jordan, UT). Finally, the size of DDs formulated with cooled compression were compared 
to those formulated by compression at room temperature (n = 3 for each formulation). 
 
2.2.4 In vitro experimental setup 
 
Based on a previous design, an in vitro flow system was constructed (Figure 7) 
(Xie et al. 2011). The system consisted of a pulsatile flow pump (Masterflex; Cole Parmer, 
Inc.) that propelled fluid through a 2-mm diameter silastic tube flow system. Phosphate 
buffered saline (PBS) was the solution used for all in vitro studies. PBS was maintained 
at 37 ºC and flowed at 20 mL/min. An US transducer (S5-1; Philips Medical Systems, 
Andover, MA) was positioned over the flow system, and a 3-cm tissue-mimicking phantom 
(Computerized Imaging Reference Systems, Inc., Norfolk, Virginia) was placed between 
the US probe and tubing system to mimic transthoracic attenuation. A port proximal to the 
imaging chamber allowed for either DMBs or the DDs to be infused into the silastic tubing 
at dilutions that could be adjusted.  
 To investigate the acoustic behavior of Definity agents, three different states were 
compared: DMBs, DDs, and filtered DDs. DMBs and DDs were both infused at 5.8x108 
particles/min, while the filtered DDs (containing just the < 220 nm DDs) were infused at 
3.9x1010 particles/min. Each solution was continuously infused at a rate of 1.0 mL/min into 
the proximal port connected to the 2 mm silastic tubing containing PBS flowing at 20 
mL/min. Using a triggered frame rate (2.22 Hz) and real-time imaging (56 Hz frame rate), 
the diagnostic US transducer (1.3 MHz center frequency; 3.4 MHz receiver frequency, 3  
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Figure 7. In vitro system. The in vitro system was composed of a fiberglass tank filled with 
degassed water through which a system of tubes was placed. PBS was pushed through 
the tubing system using a pump, and MB/ND solutions were infused into the inlet port prior 
to reaching the sonication field. An US probe was positioned over a phantom to mimic 
transthoracic imaging.   
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µs pulse duration) was used in ultraharmonic mode to insonate the infusion at incremental 
MIs (0.2, 0.4, 0,6, 0.8, 1.0, 1.2, and 1.45) in order to a) determine the threshold required 
to activate the DDs; and b) determine the acoustic intensity (AI) of the solutions at different 
regions along the scan plane within the field of insonation (Figure 8). The elevation plane 
of the probe was placed in parallel to the tubing network and measured AI as the solution 
crossed this imaging field. At a flow rate of 20 mL/min, the particles were exposed to the 
insonation field for five seconds, which resulted in cumulative frame rate exposures of 280 
frames during real-time imaging and 11 frames during triggered imaging by the time the 
DMBs or DDs reached region 4 of the imaging plane (Figure 8). The flow in the tubing was 
0.33 mL/sec, and the tube volume exposed to ultrasound volume was 1.75 mL. Thus, the 
500 ms time interval between frames at 2 Hz allowed only partial replenishment of the DD 
and DMB between frames. AI in regions 1-4 demonstrated in Figure 8 were analyzed with 
QLAB software (Philips Medical Systems, Andover, MA). 
  
2.2.5 In vivo experimental setup 
 
All studies performed were approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska Medical Center. Four normal pigs (closed chest 
model) with normal left ventricular contractility (confirmed by two expert cardiologists) 
received an intravenous (IV) infusion of 10% DMB while a Philips S5-1 transducer (Philips 
Medical Systems) was used to perform real-time imaging (35 Hz frame rate) and 1:1 
triggered end-systolic imaging in ultraharmonic mode (1.3 MHz center frequency, 3.4 MHz 
receiver frequency) at MIs of 0.2, 0.4, 0.7, 1.0 and 1.2. This same procedure was repeated 
with an IV infusion of 10% DDs.  
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Figure 8. Measurement of acoustic intensities in the in vitro system. AI of the contrast 
agents was measured at four different points along the US imaging space (regions 1-4), 
with region 1 most proximal to the entry of the contrast agent to the US field and region 4 
most distal to the entry of the contrast agent to the US field. In this example, the MI was 
1.0. (A) DMBs at 2-Hz frame rate; (B) DDs at 2-Hz frame rate; (C) DMBs at 56-Hz frame 
rate; (D) DDs at 56-Hz frame rate. 
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Background-subtracted AI was compared within the LV cavity, the anterolateral 
myocardium, and the anteroseptal myocardium at end-systole at each MI and between 
the two imaging modes (Figure 9). An established quantitative AI measurement software 
(QLAB version 9) was used to compare AIs in the different regions for both in vitro and in 
vivo measurements. For in vitro studies, the different regions were chosen along a 
longitudinal plane to assess for activation and destruction (Figure 8). For in vivo studies, 
different regions were chosen to determine whether different degrees of acoustic 
activation resulted in different myocardial contrast enhancement within normal zones. The 
background intensity was defined as the decibels (dB) present in each region of interest 
before contrast administration. 
 
2.2.6 Statistical Analysis 
 
Differences in AI in the different horizontal regions in Figure 8 within the flow 
system at different frame rates and different MIs were compared by two-way analysis of 
variance (ANOVA). An unpaired Student’s t-test was used to find differences in AIs 
between DMBs and DDs at the same MI. All data are presented as mean ± SD. Due to 
the multiple controlled comparison in the in vitro studies, a p value < 0.01 was considered 
statistically significant when comparing AIs produced by equivalent concentrations of DDs 
versus DMBs. For in vivo comparisons of DDs and DMBs, a p value < 0.05 was considered 
statistically significant. The AI of the filtered DDs was not compared to the other 
formulations due to higher concentration of the smaller DDs used in the in vitro studies, 
and the main objective of using the filtered DDs was to determine whether contrast could 
be produced from these smaller NDs.  
 
  
    
 
36 
 
Figure 9. Measurement of acoustic intensities within the heart. The intensity of the contrast 
agents was measured in three different areas of the heart: (A) anteroseptal myocardium, 
(B) LV cavity, and (C) anterolateral myocardium. 
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2.3 Results 
2.3.1 Sample Sizing 
The DDs had a polydisperse distribution, with diameters ranging from 
approximately 50 to 1,000 nm, and with the largest concentration in the 250 nm range 
(Figure 10A). Three peaks were prominent, with the first two most likely representing the 
previously described bimodal distribution of ND formation with perfluoropropane (Porter 
et al. 2016). The smaller third peak may be due to MB formation or DD coalescence. This 
size range was similar to that seen with the 6 atm (median, 294 nm; range, 175-500 nm) 
and 9 atm (median, 261 nm; range, 150-450 nm) pressures using the balloon insufflator. 
The 12 atm pressure had a median size of 386 nm and range from 250-600 nm. After 
filtering the DD solution with the 220-nm filter, the mean size of the droplets from the six 
different samples ranged from 94 ± 22 to 150 ± 46 nm (Figure 10C). The DMBs had a size 
range from 600 to 5800 nm (Figure 10B), with the largest concentration in the 800-1000 
nm range. In the experiments determining the effect of temperature on size, the DDs 
formulated with cooled compression had a mean diameter that ranged from 206 ± 79 nm 
to 217 ± 79 nm, and the DDs formulated with room-temperature compression had a mean 
diameter that ranged from 179 ± 62 nm to 188 ± 58 nm. Figure 11 shows a representative 
sample of the sizes acquired using the Zetasizer.  
 
2.3.2 In Vitro Studies 
 
While imaging at 56 Hz, DMBs exhibited higher AIs at low MIs, which diminished 
as the MI was increased (p < 0.001). As seen in Figure 12A, the AI of region 3 was 37 ± 
2 dB at an MI of 0.2, which increased to 41 ± 3 dB at an MI of 0.4, following which AI 
progressively decreased to 23 ± 2 dB when an MI of 1.45 was reached. The AI for DMBs   
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Figure 10. Microbubble and nanodroplet size distribution. Mean diameter ranges of the (A) 
DDs, (B) DMBs, and (C) filtered DDs acquired using the Nano Zetasizer. 
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Figure 11. The effect of temperature on size of formulated DDs. (A) A representative image 
of the sizing distribution measured when the DDs were formulated through cooled 
compression; (B) a representative image of the sizing distribution measured when the DDs 
were formulated with room-temperature compression. 
  
A 
B 
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Figure 12. Acoustic intensity of DMBs. AIs of DMBs in (A) real-time and (B) triggered 
modes. *p < 0.01 when two-way ANOVA was used to compare the AIs of the four different 
regions at each MI. 
 
  
0.20 0.40 0.60 0.80 1.00 1.20 1.45
-10
0
10
20
30
40
50
Mechanical Index
Ac
ou
st
ic 
In
te
sit
y (
dB
)
Definity MB (56 Hz)
Region 1
Region 2
Region 3
Region 4
0.20 0.40 0.60 0.80 1.00 1.20 1.45
-10
0
10
20
30
40
50
Mechanical Index
Ac
ou
st
ic 
In
te
sit
y (
dB
)
Definity MB (2 Hz)
Region 1
Region 2
Region 3
Region 4
A
B
* * * * * **
* * * * * **
    
 
41 
was maximal in regions 1 and 2 at higher MIs (p < 0.001). When imaging at 2 Hz (Figure 
12B), AI increased at a MI of 0.4 (compared with 0.2) and then demonstrated little variance 
as the MI was increased and among different regions of the US field (p = 0.40). There was 
no significant difference in AI in the four regions at any of the MIs tested when imaging at 
2 Hz (p = 0.42). 
DDs produced visually-evident contrast only at the higher range of MIs at both 56 
and 2 Hz (Figure 13A and 13B). There was a consistent threshold of activation at an MI 
of 0.8 at both frame rates. At 56 Hz, regions 2 and 3 had the highest AI at the higher MIs 
(p < 0.002), with region 3 having a significantly higher AI than DMB at MIs of 1.2 and 1.45 
(p = 0.04 and p < 0.001, respectively; Figure 13A). At the triggered frame rate (Figure 
13B), the DDs exhibited similar AI to DMBs in all regions when at the highest two MI 
settings (1.2 and 1.45). 
 At 56 Hz, the AI produced by the filtered DDs followed a similar pattern to the 
unfiltered DDs, exhibiting negligible AI at low MIs and significantly increased AI at high 
MIs (Figure 14A). Figure 14A depicts the changes in region 3 for the filtered DDs, which 
had an AI of 2 ± 1 dB at an MI of 0.2, remained at a negligible value until 0.8, and then 
sharply increased to 29 ± 5 dB at an MI of 1.45 (p < 0.001). This was also seen at the 2 
Hz FR (Figure 14B). 
 
2.3.3 In Vivo Studies Comparing DDs with DMBs 
 
When imaging at 56 Hz at an MI of 0.2, there was little to no AI detected with DDs 
in the LV cavity (0 ± 0 dB) or the myocardium (Table 2; Figure 15A). At an MI of 0.7, 
however, there was contrast in the LV cavity and anteroseptal myocardium (35 ± 6 and 9 
± 6 dB, respectively). With triggered imaging (Figure 15B), the DDs again produced  
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Figure 13. Acoustic intensities of DDs. AIs for DDs in (A) real-time and (B) triggered modes. 
Acoustic activation of the DDs required higher acoustic pressures (MI approximately 0.8 
and higher); however, at these pressures, destruction of the formed MBs also occurred. 
*p < 0.01 when two-way ANOVA was used to compare the AIs of the four different regions 
at each MI. 
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Figure 14. Acoustic intensities of filtered DDs. AIs for filtered DDs in (A) real-time and (B) 
triggered modes. Acoustic activation of the DDs required higher acoustic pressures (MI 
approximately 0.8 and higher); however, at these pressures, destruction of the formed 
MBs also occurred. *p < 0.01 when two-way analysis of variance was used to compare 
the AIs of the four different regions at each MI. 
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Figure 15. Acoustic intensities in the LV cavity. AIs acquired in the LV cavity during (A) real-
time and (B) triggered imaging modes. 
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significant AI only when increasing the MI from 0.2 (0 ±1 dB) to 0.7 (38 ± 9 dB) (p < 0.01). 
There was also an increase in AI from MIs of 0.2 to 0.7 in the anteroseptal myocardium, 
from 1 ± 1 to 13 ± 6 dB (p < 0.05), and anterolateral myocardium, from 0 ± 1 to 20 ± 9 dB 
(p < 0.05) (Table 2, Figure 16). In comparison, DMBs produced myocardial contrast only 
during 2 Hz imaging and not at 56 Hz (Figure 16), but they produced contrast in the LV 
cavity at all MIs tested (14 ± 4 dB at 0.2, 35 ± 7 dB at 0.7, and 35 ± 6 dB at 1.2).  
 
2.4 Discussion 
 
The main findings of this study are that the contrast produced from DDs is 
significantly different from DMBs, when at the same concentration, under conditions 
typically used for transthoracic imaging of MBs. DDs require a higher MI to produce 
contrast and produce greater myocardial contrast in real time at higher MIs. Figures 10 
and 11 demonstrate the vial-to-vial differences that result in size distribution differences 
of DDs formulated. Our in vitro studies demonstrate that one reason for greater contrast 
in real time may be related to the activation and destruction process of the DDs within the 
imaging plane when compared with the destruction-only process seen with DMBs. In the 
microcirculation, this results in contrast during real-time high MI imaging that may allow 
better detection of myocardial perfusion abnormalities and, potentially, detection of 
regions of altered endothelial permeability. 
 
2.4.1 In Vitro Comparisons 
 
 By placing the long axis of the US beam longitudinally oriented to flow in the in 
vitro studies, we were able to observe the acoustic behavior as a function of frame rate 
and identify the MIs that DMBs and DDs produced contrast in real-time before undergoing  
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Table 2. Acoustic intensities in myocardial regions. AI in decibels acquired in 
different myocardial regions of interest in four normal pigs. *p < 0.05 when comparing the 
two frames rates (2 Hz and 56 Hz) for each form at the same MI. 
  
 Anteroseptal Anterolateral 
 DMB DD DMB DD 
MI 2 Hz 56 Hz 2 Hz 56 Hz 2 Hz 56 Hz 2 Hz 56 Hz 
0.2 0 ± 1 0 ± 0 1 ± 1 0 ± 0 3 ± 2 0 ± 0 0 ± 1 0 ± 0 
0.7 17 ± 5 0 ± 2* 13 ± 6 9 ± 6 20 ± 6 4 ± 4* 20 ± 9 13 ± 4 
1.2 15 ± 4 5 ± 4* 24 ± 3 10 ± 5* 20 ±11 6 ± 3 24 ± 4 11 ± 3 
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Figure 16. Anteroseptal myocardial contrast enhancement. Real-time differences in 
anteroseptal myocardial contrast enhancement (arrows) with real-time imaging (35-Hz 
frame rate) at an MI of 1.0 of (A) DDs and (B) DMBs. 
    
 
48 
destruction. We observed consistent contrast intensity from DMBs as the MI increased 
from 0.2 to 1.45 with triggered imaging. However, with the higher frame rates used for 
real-time imaging, the higher MIs resulted in destruction of MBs, and AIs decreased 
significantly by regions 3 and 4 (Figure 13A). Thus, the recommended optimal MI for real-
time imaging of DMBs is at lower MIs (Porter et al. 2014). 
 On the other hand, DDs were not detectable even at low MIs in either triggered or 
real-time mode. This indicates that the reactivation of the DDs requires a certain degree 
of acoustic energy to overcome the Laplace pressure that otherwise maintains the liquid 
form of the perfluorocarbon despite being in a superheated state (Sheeran and Dayton 
2014). Once a MI was reached that activated the DDs, there was a progressive increase 
in AI as the MI was increased further with either real-time or triggered imaging mode, 
especially in regions 2 and 3 (Figure 14). In region 4, in real-time mode, there was a 
plateau in AI at the highest MI setting, most likely because of destruction of the activated 
MBs after exposure to multiple US frames. Overall, this indicates that a higher MI will be 
required to image DDs, and that the DMBs produced may be imaged in real-time only for 
a finite number of frames in regions of low physiologic flow rates. This was subsequently 
verified in our in vivo studies, in which myocardial contrast was evident within the 
microcirculation during the DD infusion but not the DMB infusion.  
 
2.4.2 Potential Clinical Application of Using DDs for Cardiovascular Imaging 
 
One potential application for imaging with DDs may be in detecting regions of 
altered endothelial permeability, as the smaller sized DDs may pass into extravascular 
spaces and be detected with high-MI US following extravasation. Therefore, we sought to 
determine whether DDs < 220 nm could be detected with the transthoracic US frequencies 
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and MIs. We found that the acoustic behavior of the filtered DDs was similar to that of the 
unfiltered forms but required higher concentrations to produce equivalent AI. This is most 
likely due to the smaller formed DMBs from this formulation. Nonetheless, because we 
could activate them, it may be possible to detect these smaller DDs after they have 
crossed the defective endothelial barriers that exist in myocardial infarct zones or within 
tumor vasculature. 
 A second clinical application would be for enhanced myocardial perfusion imaging. 
For the in vivo studies, we only compared the DDs with DMBs to test the acoustic 
characteristics of equivalent numbers of NDs and MBs. Similar to in vivo studies, DMBs 
had higher contrast when imaged at lower MIs during triggered imaging. Within the 
myocardium, the DMBs produced very little contrast when imaging at the 35 Hz frame rate 
higher MIs because the slow capillary flow does not permit replenishment at this rapid 
frame rate (Wei et al. 1998). Therefore, myocardial contrast was produced only when 
using triggered end-systolic imaging, in which the destruction frame rates were reduced 
significantly and DMB replenishment could occur between frames. In comparison, the DDs 
had detectable myocardial contrast during real-time imaging at higher MIs. Similar to the 
in vitro studies, the MI of 0.7 appeared to be the threshold at which activation of the DDs 
occurred in both the cavity and microcirculation with both triggered and real-time imaging 
(Figure 15, Table 2). With successive increase of MI above 0.7, myocardial contrast was 
evident within the myocardium (Figure 16) even at higher frame rates. This would appear 
to indicate that there was activation of DDs within the capillaries and sufficient time to 
visualize these DMBs before they were destroyed. This would also explain why the 
myocardial AI of the DDs increased further at the triggered frame rates, where the 
destruction of any formed DMBs was reduced. Because DMBs produce greater intensity 
at higher MIs (Masugata et al. 2001), microcirculation imaging of activated DDs at higher 
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frame rates and MIs may allow more robust real-time imaging of perfusion and better 
quantification of perfusion abnormalities.  
 
2.4.3 Limitations 
 
The differences in AI observed with reactivated DMBs may also be due to changes 
in shell behavior once reactivated (Reznik et al. 2014). Although others have observed 
expansion-dominated behavior of vaporized DDs as opposed to compression-only 
behavior seen with lipid-encapsulated DMBs, it is unlikely that such a different response 
would explain the difference we observed, because the same shell was present for both 
the DMBs and the acoustically activated DDs. Furthermore, the DMBs and DDs exhibited 
similar AIs at high-MI triggered ultrasound pulses, whereas one would expect different 
intensities if the formed DDs were exhibiting expansion-dominated oscillations. 
Nonetheless, further study of this with ultra-high-speed optical imaging is needed to 
determine shell behavior during insonation of DMBs versus activated DDs.  
 The AI of DMBs at the low-MI setting was not as high as what was observed in 
vitro. This most likely is related to our ultraharmonic imaging frequency (1.3 MHz transmit, 
3.4 MHz receive), which may require a higher MI to produce contrast compared with very 
low MI pulse sequence schemes, and to DMB destruction at the high frame rates (even at 
a low MI setting), as well as lower concentration of DMBs reaching the LV cavity compared 
with the flow chamber. Destruction of DMBs even at the low-MI, high-frame rate setting is 
supported by the observation that triggered low-MI frame rates produced some LV cavity 
contrast with DMBs, whereas the 56-Hz frame rate did not (Figure 13). 
 It is unclear from our study what the optimal acoustic conditions would be for high-
MI imaging of the microvasculature. In the flow studies, the repeated exposure to the high-
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MI 56-Hz frame rate resulted in destruction of DMBs formed from DDs. Optimal 
opacification of the LV cavity in our in vivo studies was achieved at higher MIs. In this 
setting, the DDs were imaged in a cross-sectional view, which may have reduced 
destruction after activation. Further study is needed to determine how to optimize high-MI 
imaging of the DDs for endocardial border resolution in the LV cavity and perfusion 
imaging in the microvasculature. 
 Finally, it is unclear how applicable our findings with compressed DMBs would 
apply to other commercially-available contrast agents. These agents either have different 
gases (sulfur hexafluoride) or different shells (albumin), and thus, it is unclear whether 
they would form stabilized NDs that could be activated for imaging.  
 
2.5 Conclusion 
Commercially-available lipid-encapsulated perfluoropropane DMBs can be 
condensed into submicrometer DDs and reactivated with diagnostic US. The DDs range 
in size from 50 to 1000 nm, and all size ranges can be activated with diagnostic US but 
require higher MIs to do so. Targeted in vivo activation of the DDs produces myocardial 
contrast in real-time at higher MIs. This form of targeted real-time imaging may improve 
the detection of myocardial contrast defects for ischemia detection and may be a method 
of getting acoustically detectable agents across defective endothelial membranes for other 
diagnostic and therapeutic applications.  
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Chapter 3 
 
 
Myocardial infarct imaging with acoustically activated 
nanodroplets 
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3.1 Introduction 
The perfluorocarbons that are utilized for commercially-available MB preparations 
can be condensed into a liquid phase and remain in this state even as they remain at room 
temperature (Arena et al. 2015; Matsunaga et al. 2012; Sheeran et al. 2015; Sheeran and 
Dayton 2014). One of the most common commercially-available MBs, Definity, contains 
perfluoropropane (C3F8) gas that can be condensed to a ND form under cooled pressure 
and maintained in this superheated liquid state even at body temperature. Our group has 
previously demonstrated that diagnostic US pressures at or above 1.0 MI can reactivate 
these DDs (Porter et al. 2016; Choudhury et al. 2017). 
 When in this condensed phase, the DDs are nanometer in size (instead of micron-
sized when in MB form) and remain in this phase even following intravenous injection 
(Choudhury et al. 2017). Figure 17 shows one potential advantage of this size is that the 
particles could cross defective endothelial cell junctions that exist following acute 
myocardial ischemia and ischemia-reperfusion (Hollander et al. 2016). Since the DDs are 
more stable than the DMBs, they could accumulate within the infarct zone where, at some 
time point following venous injection, they could be activated and imaged by high MI US 
(Figure 18). Since DD velocity within the infarct zone would be expected to be relatively 
low with respect to normal microcirculation and left ventricular cavity, selective activation 
and imaging of DDs within the infarct zone may be possible. This may result in an infarct 
enhancement zone similar to what is seen with delayed-enhancement magnetic 
resonance imaging. In this study, we hypothesized that a) intravenously injected 
perfluoropropane DDs would accumulate within an infarct zone, and b) acoustic activation 
and imaging with diagnostic US would detect this zone and correlate with infarct size. 
Finally, in a larger animal model, we tested whether harmonic imaging at a low frame rate 
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Figure 17. Definity nanodroplet movement through blood vessels. When DDs travel through 
blood vessels that are surrounded by healthy endothelium (top panel), they remain within 
the intravascular compartment. However, in areas where infarcted endothelium (bottom 
panel) exists, the cells junctions are leaky, and DDs are small enough to cross into the 
interstitial space (extravascular compartment).   
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Figure 18. Definity droplet activation and imaging sequence. Left ventricular short axis US 
images. Left: Prior to DD injection, US imaging would not highlight regions of infarction. 
Middle: Accumulation of DDs within the infarct zone after injection and some detection 
with low MI US imaging. Right: With high MI activation of the DDs and subsequent low MI 
imaging, areas of infarction would be highlighted. 
  
    
 
56 
(triggered end-systolic or 10 Hz) could selectively enhance the infarct zone.  
 
3.2 Methods 
3.2.1 Microbubble and Nanodroplet Formulation and Characterization 
Definity® (Lantheus Medical, N. Billerica, MA) was used in all the studies 
('Definity® (perflutren lipid microsphere) [package insert]. Lantheus Medical Imaging, N. 
Billerica, MA'  2018). The DMB vials were stored at 4 °C. DMB solutions were warmed to 
room temperature (25 °C) and activated via mechanical agitations (Vialmix shaker, Bristol-
Myers-Squibb, New York, NY) for 45 sec. DDs were formulated according to a previously 
described protocol (Porter et al. 2016; Choudhury et al. 2017). Briefly, 2 mL vials of 
suspended DMBs were agitated, the DMB solution was diluted two-fold with normal saline, 
and submerged in a 70% isopropyl alcohol bath at a temperature between -10 °C and -15 
°C for 3 min. Subsequently, manual pressure was applied until persistent clearing of the 
solution was visually evident for 1 min (Figure 6). The DDs and DMBs were both sized (n 
= 3 for each solution) using a Nano Zetasizer (Malvern Nano ZS, Malvern Instruments 
Ltd., Malvern, Worcestershire, U.K.), which is capable of sizing particles from 50 nm to 10 
µm diameter. The Zetasizer utilizes dynamic light scattering to determine particle size. 
DMB and DD concentrations were determined with Nanosight light scattering analysis 
(Malvern, Worcestershire, UK).  
 
3.2.2 Fluorescent Droplet Formulation 
To verify the presence of DDs within the infarct zone, the DMBs were fluorescently 
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labeled with a commercially-available lipophilic fluorophore, 
dioctadecyltetramethylindocarbocyanine (DiI), prior to DD formulation. DiI (2 µL/vial) was 
added to vials of DMB prior to mechanical agitation (Cui et al. 2013). The DDs were then 
formulated using the same compression technique described for non-fluorophore 
containing DDs. A 200 µL (rats) or 1 mL (swine) bolus injection of the fluorescently-tagged 
DDs was administered to the animal after completion of all imaging protocols. Animals 
were euthanized 10 min post-injection. Post-mortem, 1 mm short axis sections of the 
myocardium corresponding to the location used for short axis imaging and for 
triphenyltetrazolium chloride (TTC) staining were collected.  
 
3.2.3 Rat Model of Acute Myocardial Infarction 
The Institutional Animal Care and Use Committee at the University of Nebraska 
Medical Center approved all rodent studies. Fourteen rats (Sprague-Dawley, Charles 
River, Portland, MI) underwent left anterior descending (LAD) coronary artery ligation. 
Animals were anesthetized (isoflurane 2-2.5%) and intubated for ventilation for the 
duration of the surgery. A left thoracotomy was performed at the 4th intercostal space to 
allow for visualization of the LAD. Prior to ligation of the artery, 2-3 drops of 1% lidocaine 
were placed on the heart to prevent arrhythmias. The LAD was ligated 1-2 mm below its 
origin from the aorta. Following confirmation of a persistent occlusion, the chest incision 
was closed, and the rats were weaned from the ventilator. The animals were monitored 
for one hour after surgery to ensure that spontaneous ventilation was regained. Next, the 
animals were extubated and allowed to recover. 
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3.2.4 Rat Model Ultrasound Imaging 
After 48 hours of recovery, the animals were re-anesthetized (isoflurane; 4% 
induction, 1.5-2% maintenance). A Siemens Acuson Sequoia with a 15L8 transducer (7-
MHz fundamental frequency, Siemens Healthcare, Mountain View CA) was used to 
perform transthoracic imaging. Once a short axis mid-papillary muscle image was 
obtained, the transducer was placed in a fixed position over the chest wall using a cross 
clamp and stabilized with a ring stand. Figure 19 shows the experimental setup for rat US 
imaging.  
 Baseline two-dimensional images were attained to assess regional wall motion. 
The imaging modality was then switched to contrast pulse sequencing as described below. 
To begin the imaging protocol, 200 µL intravenous (IV) injections of diluted DMBs were 
administered to the animals during low MI (0.5 MI) imaging (triggered at 1 frame every 3 
cardiac cycles). Any contrast enhancement was noted at this MI setting, and contrast 
defects that were visualized at any time point where there was a visually evident defect 
were planimetered (Figure 20). At 2 min following injection, any residual myocardial or 
cavity contrast was noted at the 0.5 MI setting, following which the MI was transiently 
increased to 1.5 for a period of 15-20 sec to examine for any changes in contrast intensity. 
The IV line was flushed at 10 min following the last DMB injection to remove any residual 
MBs in the line and was visually confirmed by US.  
 Following the DMB injection, a 200 µL IV injection of dilute DD was administered. 
Visualization of contrast while at 0.5 MI was again noted. The MI was increased to 1.5 
(while triggering at end systole once every three cardiac cycles) at a time period of 2 to 6 
min after DD injection. Contrast within the LV cavity and myocardium was noted. Special 
attention was paid to any enhancement within the hypokinetic infarct zone (termed TEZ).  
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Figure 19. Rodent imaging experimental setup. During the experiment, the animals were 
maintained on isoflurane anesthesia, and they were monitored via EKG as well as 
hemodynamically. The US transducer was used to find the appropriate short-axis window 
before its position was fixed in space using a ring stand. A cannula was placed in the 
jugular vein to provide access to administer DMBs or DDs. 
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Figure 20. Transient enhancement zone quantification protocol. The method of quantifying 
the zone of transient myocardial enhancement (planimetered area outlined by black 
arrowheads in the lower left panel) observed within the akinetic myocardium during brief 
high MI (1.5) imaging at two minutes following a 200 µL injection of intravenous DDs. SS 
indicates the sternal shadow. 
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The TEZ was defined as the planimetered area of transient myocardial contrast 
enhancement observed within the hypokinetic zone as the MI was increased to 1.5 which 
then disappeared on subsequent triggered frames at the high MI setting (Figure 20). With 
contrast pulse sequencing, the non-infarct zone outside the TEZ typically exhibited 
persistent myocardial contrast enhancement in this time period (Figure 20). 
After completing the imaging protocol, the location of the diagnostic US probe was 
marked to ensure the same location was prepared for subsequent histology, and the probe 
was removed. The animals were given a 200 µL injection of the fluorescently labeled DDs 
(formulated as described above). TTC staining for infarct size was performed at 37 °C 
using standardized techniques (Redfors, Shao, and Omerovic 2012).  
 
3.2.5 Porcine Model of Acute Myocardial Infarction 
The Institutional Animal Care and Use Committee at the University of Nebraska 
Medical Center approved all porcine studies. Five swine (Yorkshire Cross, University of 
Nebraska Swine Research Unit) were maintained on a normal diet. The mean weight of 
the animals was 30.9 ± 4.2 kg. The animals were preanesthetized with a mixture of 
xylazine (2.2 mg/kg), ketamine (2.2 mg/kg), and telazol (4.4 mg/kg). A cannula was placed 
in a vein in each ear, and the animals were intubated and anesthetized (isoflurane; 
induction at 4-5%, maintained at 1.5%). The animals were maintained on a respirator at a 
volume of 10 cc/kg of air at a rate of 15 BPM. During contrast administration, the animals 
were maintained on room air. Heart rate, oxygen saturation, and blood pressure were 
monitored throughout the study. Dobutamine (0.5 – 3 mcg/kg/min) was given to maintain 
blood pressure. Lidocaine (0.6 – 50 mcg/kg/min) was administered to prevent arrhythmias. 
Amiodarone (2 – 12 mg/kg) was also given in bolus injections to prevent arrhythmias. 
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Femoral arterial and venous access was attained for administration of UCAs as 
well as hemodynamic monitoring. Baseline 2-dimensional echocardiographic images and 
12-lead EKGs were acquired. An 8-French hockey stick was guided into the LAD for 
balloon catheter insertion. Baseline angiograms (C-arm system, GE Healthcare, Salt Lake 
City, UT) were captured. The angiograms were used to measure the diameter of the LAD 
and determine the size of balloon required for 100% inflation. The balloon was inflated to 
100% LAD diameter twice (30 sec each) and then a third time for 90 min. The occlusion 
of the artery was confirmed with angiography as well as with US. If the animal entered 
ventricular fibrillation at any time during the procedure, the balloon was immediately 
deflated. Following occlusion, angiography, echocardiography, and 12-lead EKG were 
repeated. At 40 min post-occlusion, echocardiography, angiography, and 12-lead EKG 
were repeated. At 75 min post-occlusion, echocardiography and 12-lead EKG were 
repeated. At 90 min post-occlusion, angiography was performed, the balloon was deflated 
to allow for recanalization of the LAD, and angiography was repeated to determine 
patency of the infarcted artery. After the LAD had been reperfused for 20 min, the animals 
were removed from anesthesia and extubated.  
 
3.2.6 Porcine Model Magnetic Resonance Imaging 
 After 48 hours of recovery, the animals were pre-anesthetized with a mixture of 
xylazine (2.2 mg/kg), ketamine (2.2 mg/kg), and telazol (4.4 mg/kg). The animals were 
maintained on 1.5% isoflurane. Cannulas were placed in one vein in each ear, and the 
animals were intubated. Femoral venous access was attained before the animal was 
moved for MRI. The animals were placed on a ventilator to allow for pausing breaths 
during scans.  
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Cardiac MRI scans were performed using a 1.5 Tesla Magnet (Philips Achieva XL: 
Best, The Netherlands). MRI was critical to determine the size and location of the 
infarction. Imaging sequences included standard steady state free precession imaging (TR 
3.0 msec, TE 1.3 msec) followed by T2 weighted spin echo images in the same short axis 
views. Next, 0.2 mmol/kg gadopentate dimenglumine (Magnevist: Bayer) was 
administered. After 10 minutes of injection, DE-MRI was performed in the same short axis 
offsets.  
   
3.2.7 Porcine Model Ultrasound Imaging 
 Immediately following the cardiac MRI, the echocardiographic imaging protocol 
was performed. First, two femoral arterial lines were placed using an 8-French introducer. 
A Philips S5-1 transducer (Philips Healthcare) was used to attain baseline 2-D, short-axis 
US images corresponding to a region with a resting wall motion abnormality and a scar 
zone revealed through DE-MRI. The imaging schemes used for this model were based on 
observations from the imaging protocol performed on the rat model, where multi-pulse 
schemes (contrast pulse sequencing) appeared to activate DDs within the LV cavity and 
normal microcirculation. Due to this observation, we believed that single pulse harmonic 
imaging at slow frame rates (or triggered frame rates) would permit activation and imaging 
of only the slow moving or stationary DDs that had leaked into the infarct zone. 
Ultraharmonic imaging (1.3 MHz transmit frequency and 3.4 MHz receiver frequency) at 
10 Hz or triggered to end systole at one frame every cardiac cycle was tested. The second 
mode tested was a harmonic only mode (1.7 MHz transmit frequency and 3.4 MHz 
receiver frequency) at low frame rates (10 Hz or end systolic triggered).  
The two imaging settings were tested approximately 2-4 minutes after IV injection 
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of 1.0 mL DDs (1:1 dilution). MIs of 0.7, 1.0, or 1.3 were tested. Images were digitally 
stored. Prior to sacrifice, the animals received an IV injection of fluorescently-tagged DDs 
(1:1 dilution), then a balloon catheter was advanced to the location of the original LAD 
occlusion and inflated to re-occlude the infarcted vessel (in cases of recanalization). The 
animals were sacrificed, and post-mortem TTC staining was completed to define the 
extent of the infarct zone in the same short axis plane used to detect for acoustic 
activation. Infarct size and risk area were measured using planimetry. 
 
3.2.8 Image Analysis 
In the rat model, quantitative measurements of the TEZ and the contrast defects 
produced by DMBs were determined by a consensus of two experienced reviewers (FX 
and TRP), blinded to the TTC and fluorescent images, using the imaging protocol 
described in Figure 20. The triggered images were digitally reviewed during the transition 
from 0.5 to 1.5 MI, which resulted in immediate left ventricular cavity and normal 
myocardial zone enhancement as well as a transient (3-4 triggered frames) enhancement 
within the akinetic zone detected on short axis two-dimensional echocardiographic 
images. The normal myocardium was distinguished from the TEZ by persistence of 
myocardial contrast beyond the transient enhancement. The TEZ was planimetered with 
ImageJ (https://imagej.nih.gov/ij/) software by analyzing the TEZ during and after 
enhancement side-by-side, as shown in Figure 20. In pigs, any selectively enhanced zone 
that was seen at the 1.0 or 1.3 MI, while in low frame rate imaging, was planimetered. 
 Fluorescent microscopy (Carl Zeiss Canada, Toronto, ON) was performed to 
identify any locations exhibiting emission spectra near 590 nm (emission spectra for DiI). 
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The ImageJ software was used to also quantify the fluorescent zone and unstained TTC 
area. 
 
3.2.9 Statistics 
A p < 0.05 was considered statistically significant. Statistical analysis was 
performed using SigmaPlot V13.0 (Systat Software, Inc., San Jose, CA). The size of the 
TEZ was compared to three other modes of infarct size detection. The first was 
planimetered size of the contrast defect obtained following DMB injections, which was 
chosen from triggered frames within two minutes following the DMB injections. The second 
comparison was with the size of the infarct zone on post-mortem TTC staining. The final 
comparison was the infarct size determined by confocal microscopy compared to TTC 
staining. Linear regression was used to compare the defect size determined with TTC 
staining and the fluorescent area with both the contrast defect observed following DMB 
injections and the TEZ observed with DD activation at > 2 min following DD injection. In 
six rats receiving a second DD injection, planimetered TEZ size from the second versus 
the first injection using the same protocol described in Figure 20 was compared using 
Bland-Altman analysis. In pigs, correlation coefficients were used to compare the 
selectively enhanced area and the infarct zone by TTC.  
 
3.3 Results 
3.3.1 Microbubble and Nanodroplet Sizing and Concentrations 
The formulated DDs had a polydisperse size distribution, with two main peak sizes 
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of 82 nm and 427 nm. The DMBs were monomodal with a mean size of 767 nm. The 
number of DDs in the 200 µL solution was 1.7x1012, while the concentration of DMBs in 
the 200 µL solution was 4.9x1011. Note that these are larger numbers than recorded in the 
package insert because of the larger size range of measured DMBs and DDs that could 
be sized with the Zetasizer ('Definity® (perflutren lipid microsphere) [package insert]. 
Lantheus Medical Imaging, N. Billerica, MA'  2018). DD doses tested in pigs were 8.5x1012 
particles/mL in the bolus injections.  
 
3.3.2 Infarct Zone Detection in the Rodent Model 
There were no changes in heart rate (mean heart rate 309 ± 29 beats/min prior to 
injection and 291 ± 31 beats/min post-injection), respiratory rate (mean respiratory rate 48 
± 15 breaths/min prior to injection and 40 ± 12 breaths/min post-injection), or oxygen 
saturation (mean oxygen saturation 96 ± 5 % prior to injection and 97 ± 3 % post-injection) 
observed following DMB or DD injections in any rat. By TTC staining, the infarct size 
ranged from 0 to 11.6 mm2 of the mid-papillary muscle short axis plane imaged. Of the 14 
animals, 11 had transmural infarctions and 3 had either no or a non-transmural infarction 
(Table 3).  
 DMB injections consistently produced a contrast defect within the infarct zone at 
0.5 MI immediately following bolus injection in all but two rats, which were found to have 
no or smaller-sized infarctions (Table 3). In all rats that received DMB injections, 
myocardial contrast in the normal zones had washed out by two minutes (Figure 21; 
bottom panel). The myocardial contrast defect size obtained within the first two minutes 
following bolus injection when imaging at 0.5 MI correlated with infarct size by TTC staining 
(r = 0.81; p < 0.001; Figure 22). When the MI was transiently increased to 1.5 at two  
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Table 3. Measurements of the infarct zone in rodent model of acute 
myocardial infarction. Individual measurements of the contrast defect determined 
with intravenous DMB injections versus the TEZ measurements at 2-5 minutes post 
intravenous DD injections. The corresponding fluorescent areas and TTC measurements 
from the post-mortem sections at the equivalent short axis plane are displayed. 
Fluorescent images could not be attained for rats 6, 13, and 14; DMB defect could not be 
quantified for rat 12. 
Rat 
DMB 
Defect (mm2) 
DD TEZ 
(mm2) 
Fluorescent 
Area (mm2) 
TTC (mm2) 
1 8.6 7.2 8.0 7.6 
2 9.4 9.4 7.6 11.6 
3 7.1 7.9 8.0 8.0 
4 10.1 10.5 7.4 11.7 
5 0 3.7 4.7 4.3 
6 8.4 8.5 * 9.0 
7 3.3 6.3 6.1 6.8 
8 6.0 6.5 15.8 6.3 
9 0 0 1.0 0 
10 0 2.1 7.3 6.3 
11 5.3 4.8 4.5 4.1 
12 * 8.0 9.2 7.9 
13 6.1 6.1 * 9.0 
14 7.5 7.8 * 10.7 
Mean ± SD 5.8 ± 3.5 6.3 ± 2.6 7.2 ± 3.5 7.4 ± 3.1 
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Figure 21. DMB imaging in rodent model. A bolus intravenous injection of DMBs at 0.5 MI 
(top panel). This demonstrated an anterior/anterolateral segment contrast defect in a rat 
with a corresponding transmural infarction in this zone by TTC staining (not shown). By 
two minutes post-intravenous injection, myocardial contrast enhancement had 
disappeared (bottom panel). SS indicates sternal shadow.  
    
 
69 
 
 
Figure 22. Rodent infarct size correlation plot. Correlation between the contrast defect size 
following DMB injection with TTC.  
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minutes or longer following the injection, no additional myocardial contrast was produced 
within the normal or infarct zones.  
In comparison, DD injections did not produce myocardial enhancement following 
bolus injection at the MI in any animal and just trace amounts of LV cavity contrast (Figure 
23; upper left panel). When the MI was transiently increased, over a 5-second period, to 
1.5 MI at two minutes post-injection, there was sudden contrast enhancement within the 
LV cavity followed by persistent enhancement in the normal myocardial segments during 
the high MI period. There was also transient myocardial enhancement (1-3 frames) within 
the hypokinetic zone (Figure 23 and Figure 24). The enhancement within the infarct zone 
typically disappeared after the third triggered high MI frame, resulting in the eventual 
appearance of a contrast defect within the TEZ (Figure 23 lower right panel, Figure 24 
lower left panel). The size of the TEZ area correlated closely with the infarct size by TTC 
staining (r = 0.94, p < 0.001; Figure 25), and the correlation of TEZ size with TTC was 
similar to that seen with a contrast defect immediately following DMB. If the MI was 
increased to 1.5 later than six minutes after injections, there was minimal evidence of DD 
activation.  
Fluorescent staining was feasible in 11 of 14 animals. In 3 animals (rats 6, 13, and 
14 in Table 3), the sections for the staining technique were not adequately prepared for 
microscopy. In the remaining 11 animals, staining was not seen within any normal 
myocardial segment (Figure 26). The planimetered area of fluorescent staining 
corresponded to the spatial location of the infarct zone by TTC (Table 3) and the TEZ. 
There was also a significant correlation between the size of the TEZ and fluorescent area 
(r = 0.67, p = 0.03).  
There was slight injection-to-injection variability in TEZ measurements with 
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Figure 23. DD imaging in rodent model. DDs were be visualized at 0.5 MI following bolus 
intravenous injection (first panel). Two minutes post-intravenous injection, as the MI was 
increased to 1.5, there was enhancement that initially began in the LV cavity (second 
panel) followed by normal myocardium before there was transient enhancement within the 
infarct zone (black arrows; third panel). The enhancement within the infarct zone 
disappeared, while contrast remained visible in the left ventricular cavity and normally 
perfused myocardium (white arrows; right panel). IVI indicates intravenous injection, and 
SS indicates sternal shadow.  
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Figure 24. DD imaging 4 minute post-injection in rodent model. At 4 minutes post 
intravenous injection of DDs, there was no contrast at 0.5 MI (left panel), but at 1.5 MI, 
there was transient enhancement within the infarct zone (arrows; second panel). This 
transient enhancement disappeared with repeated high MI imaging impulses (third panel), 
while the normal myocardium enhanced as a result of the bolus of microbubbles produced 
by acoustic activation within the LV cavity (arrows in middle panel). The corresponding 
TTC image is shown. IVI indicates intravenous injection, and SS indicates sternal shadow. 
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Figure 25. Rodent infarct size correlation plot. Correlation between TEZ and TTC after DD 
injection. 
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Figure 26. Rodent infarct size by three methods. Transient zone of contrast enhancement 
(arrows, Panel A), in the first frames after increasing MI to 1.5 in a rat with an extensive 
lateral wall infarction compared with TTC staining (Panel D). Note that after five high MI 
impulses the contrast disappears from the infarct zone (Panel B). Panel C demonstrates 
the fluorescent microscopy images of enhancement within the infarct zone (white arrows) 
from DiI-fluorophore labelled DDs given 10 minutes prior to sacrifice. 
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repeated measurements (mean difference in the six rats tested was 0.60 mm2; 95% CI for 
the mean of the difference in repeated measurements 1.30 mm2). The correlation between 
the measurements of TEZ following repeated injections was significant (r = 0.94; p < 
0.001). 
 
3.3.3 Infarct Zone Detection in the Porcine Model 
In order to activate and image solely stationary DDs that accumulate within the 
infarct zone, the imaging modality was altered in the large animal model to single-pulse 
harmonic imaging (1.3-1.7 MHz transmit, 3.4 MHz receive) at slow frame rates, with 
attempts to activate and image at two and four minutes following IV injection. Figure 27 
shows an example of how selective activation and imaging of the DDs within the infarct 
zone was possible by reducing the frame rate to triggered end-systolic imaging at an MI 
of 1.0 or 1.3. This figure also demonstrates that faster frame rates at this MI resulted in 
enhancement within normal myocardial segments as well as the LV cavity. 
Transmural infarcts were observed in four of the five pigs studied by DE-MRI and 
TTC staining (Figure 28 displays the images for all five pigs). The 1.0 mL IV injection of 
DDs consistently produced selective contrast enhancement within the infarct zone when 
using either ultraharmonic (1.3 MHz transmit, 3.4 MHz receive) or harmonic imaging (1.7 
MHz transmit, 3.4 MHz receive), and minimal cavity contrast was produced at 4 minutes 
post IV injection. The 1.0 MI setting produced optimal selective activation of the infarct 
zone. There was less far field attenuation with the 1.7/3.4 MHz setting (Figure 27). There 
was a significant correlation of infarct area size determined by TTC staining (r = 0.90, p < 
0.05; Figure 29).  
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Figure 27. Porcine selective enhancement. Selective infarct zone enhancement in Pig 5 
observed with triggered 1.0 MI imaging versus 10 Hz frame rate at 1.0 MI which resulted 
in both cavity and normal myocardial enhancement. 
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Figure 28. Porcine enhancement. Enhancement within the anteroseptal scar zone with 
either ultraharmonic high MI imaging (Pigs 1 and 3) and 1.7 MHz harmonic high MI 
imaging (Pig 4) at over 2 minutes post intravenous injection of 1.0 mL of DDs. Pig 2 did 
not have an infarction following the 90-minute occlusion; the other three pigs had 
transmural infarctions. The enhanced zone with harmonic or ultraharmonic imaging 
significantly correlated with infarct zone location on cardiac MRI and with TTC 
measurements of infarct size.  
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Figure 29. Porcine infarct size correlation plot. Significant correlation (r = 0.90, p < 0.05) 
was found between the TEZ and TTC with DD injection in the porcine model.  
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3.4 Discussion 
 The main findings of this study are that DDs formulated from DMBs have 
significantly different distribution kinetics in blood following IV injection, which alters their 
clinical application. DMBs function as pure intravascular tracers, and they can delineate 
an ischemic or infarcted zone as a contrast defect in the few seconds following a small 
bolus injection of the contrast agent. DDs, on the other hand, remain in the circulation for 
extended periods of time following injection, and they appear to cross defective coronary 
and microvascular endothelial barriers that exist in the acute infarct or ischemia setting 
(Hollander et al. 2016), resulting in DD accumulation within the risk area. Secondly, the 
DDs within this zone can be activated and imaged transiently with high MI impulses that 
utilize a nonlinear pulse sequence scheme several minutes following injection, resulting in 
delayed detection and quantification of infarction size. Thirdly, we demonstrate that 
selective enhancement of the DDs within the infarct zone is feasible using a single pulse 
low frame activation and harmonic imaging sequences.  
 The threshold for activating the DDs within the infarct zone appeared to be 1.0 MI 
or greater, with 1.0 MI activating the infarct zone selectively in the porcine model. Higher 
MI values allowed activation and imaging of DDs outside the infarct zone. The higher MI 
was similar to what has caused activation and imaging in the heart (Porter et al. 2016; 
Choudhury et al. 2017) as well as with higher molecular weight fluorocarbon nanodroplets 
(Reznik et al. 2013; Reznik et al. 2014; Li et al. 2015; Shpak et al. 2014). Previous in vitro 
and in vivo studies have also shown that DDs activate only at higher MIs, and thus, they 
exhibit a distinct difference in acoustic characteristics when compared the microbubbles 
used to formulate them (Choudhury et al. 2017). The novel discovery from this study was 
that by allowing for DD accumulation to occur within the infarct zone and by utilizing short 
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pulse activation sequences there was potential for selective infarct imaging of the 
stationary DDs that accumulated within these infarct zones. This may represent an 
alternative approach to cardiac MRI for scar detection and may even be a method for 
detecting acute inflammation, which was not tested in this study. 
While imaging at low MIs (0.5 MI) following bolus injections of DDs in the rodent 
model, there was no activation or contrast enhancement within the LV cavity or 
myocardium, while a similar concentration of intravenous DMBs produced marked 
contrast enhancement that persisted only for the first two minutes following IV injection. 
This indicates rapid clearance of DMBs from the systemic circulation, while the DDs 
appear to persist for up to six minutes following IV injection. Since the DD shell 
composition was not chemically different than the DMB, the most likely explanation is that 
the gas escaped from the DMBs due to high surface tension, while the liquid fluorocarbon 
within the DDs was at a lower surface tension and remained within the shell until either 
activation or shell metabolism.  
 The timing of DD activation and imaging within the infarct zone was a critical factor 
for determining the infarct zone location and size in the rat model of infarction. As shown 
in Figure 23, as the MI was increased to 1.5 there was cavity enhancement initially that 
was followed by transient enhancement within the infarct zone and persistent 
enhancement within normal zones. The transient enhancement in the infarct zone can be 
explained by DDs that had accumulated within the interstitial spaces of the infarct zone, 
but were unable to replenish between high MI frames. Because the multi-pulse scheme 
(Contrast Pulse Sequencing) was longer in duration than standard imaging sequences 
(Vicenzini et al. 2007), the longer exposure to US may account for the activation and 
imaging of faster moving DDs within the LV cavity and normal microcirculation.  
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This was the reasoning for the modifications of the imaging scheme for the porcine 
studies, which utilized a shorter pulse duration (harmonic single pulse) and slightly lower 
MI (1.0) at a slow frame rate (10 Hz) for imaging and activation. Higher MI values appeared 
to allow activation and imaging of DDs outside the infarct zone. A higher peak negative 
pressure has consistently been required for activation and imaging in normal myocardium 
with transthoracic imaging (Porter et al. 2016; Choudhury et al. 2017), and what has been 
observed by others for detection outside the heart with higher molecular weight 
fluorocarbon droplets (Reznik et al. 2013; Reznik et al. 2014; Li et al. 2015; Shpak et al. 
2014). In this study, we discovered that it is possible to selectively activate DDs based on 
their velocity within the microcirculation. It was assumed that DDs leaking across 
endothelial barriers into the infarct zone would have very slow random motion, and short 
pulse harmonic sequences would be able to selectively activate these at a lower MI 
threshold due to the more prolonged exposure of DDs within the scar zone to the 
sinusoidal perturbation of US that enhance vaporization (Hillenbrand et al. 2000). This 
was further improved by allowing for DD accumulation to occur within the infarct zone prior 
to attempting activation and reducing the number of DDs within the LV cavity and normal 
microcirculation at four minutes post-injection. 
 
3.4.1 Cardiovascular Clinical Application 
 Although MB contrast agents have always been considered pure intravascular 
tracers, the reformulation of them into NDs changes their characteristics and clinical utility. 
First, they could potentially be imaged at a high MI immediately after injection, allowing 
them to be reconverted back to MBs when they reach the LV cavity and assess myocardial 
perfusion as has been previously demonstrated (Porter et al. 2016). Secondly, due to their 
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longer persistence within the circulation, the NDs could be reactivated at several minutes 
following IV injection to identify areas of altered microvascular permeability, enabling 
detection and quantification of infarct size or remote ischemia as was demonstrated in this 
study. The potential for infarct zone quantification would be similar to delayed gadolinium 
enhancement MRI (Hillenbrand et al. 2000; Ingkanisorn et al. 2004; Kim et al. 1996; Kim 
et al. 1999). The technique may also be applicable to other settings where altered 
microvascular permeability and endothelial dysfunction from scarring or inflammation 
occur, such as myocarditis, infiltrative diseases, transplant rejection, or hypertrophic 
cardiomyopathy.  
 
3.4.2 Limitations 
For this study, DDs were activated after two or four minutes mainly because, at 
this time point, the DMB bolus injections were no longer producing myocardial contrast 
and were clearing the blood pool. It is unclear how long after the injection one may still be 
able to produce sufficient DD activation that would permit enhancement exclusively within 
an infarct zone. The longer the time interval, the more likely there would be less inference 
from cavity DD activation and “interfering” myocardial contrast from these formed MBs in 
normal zones. As shown in Table 3, fluorescent intensity area was spatially located with 
the infarct location, but the correlation with TEZ was weak, indicating that not all the DDs 
within the infarct zone were being activated. Furthermore, fluorescence was detected 
within the infarct zone at 10 min following injection, but DD activation was only 
demonstrable up to 6 min following injection. Although the transducers and pulse 
sequence schemes used for the current study were effective in DD activation, more 
sophisticated activation sequences may be required to obtain uniform DD activation when 
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detecting the smaller focal scars created by numerous disorders (Puett et al. 2014; Reznik 
et al. 2012).  
  
3.5 Conclusion 
DDs produced from compressed commercially-available perfluoropropane MBs 
cross defective endothelial barriers within myocardial infarct zones, and they can serve as 
a method of infarct enhancement imaging with conventional echocardiographic pulse 
sequence schemes at prolonged time periods following intravenous injection. Selective 
activation of the infarct zone is possible with intravenous DDs and a harmonic imaging 
sequence, similar to what is observed with DE-MRI. The potential for translation into 
clinical practice is high, as the pulse sequence schemes which activate the DDs within the 
infarct zone are commercially-available, as are the DMBs that were used to form the DDs.  
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Chapter 4 
 
 
Summary, Conclusion, and Future Directions 
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4.1 Summary  
 UCAs greatly improve the diagnostic power of echocardiographic images, and in 
particular, they have improved detection of abnormal regional wall motion that is often a 
result of HD (Kurt et al. 2009). MBs are ideal for use during low MI perfusion imaging as 
they can be used to detect regions of hypoperfusion that occur during acute myocardial 
ischemia (Porter et al. 2016). Unlike gadolinium, MBs are intravascular tracers and are 
unable to cross normal or defective endothelial borders. In the setting of ischemia or 
infarction, myocardial regions would appear as a zone of reduced acoustic intensity as 
opposed to enhanced regions commonly seen with infarct imaging using DE-MRI (Schuijf 
et al. 2004). There is an ongoing need to develop new techniques to rapidly delineate the 
infarcted or ischemic tissue that results from AMI. 
 In this thesis, we presented a novel method for detection and quantification of the 
infarct zone after AMI through the delayed enhancement of a PCA. Definity was chosen 
as the precursor because of its octafluoropropane gaseous center, and previous studies 
have demonstrated that after compression, perfluoropropane remains in its liquid form 
even at body temperature (Matsunaga et al. 2012).  
In Chapter 2, we began by characterizing the properties of the DDs formed from a 
MB precursor and then performed in vitro and in vivo experiments to understand the 
acoustic behavior of the small DDs. In order for the DDs to be used as an extravascular 
contrast agent, it was critical to determine if the size of the particles created would be 
small enough to traverse the defective endothelium that results from AMI. Shekhar et al. 
recently completed a study exploring the effect of temperature on size and stability of 
DMB. This group found that quantifying the size distribution of this particle was difficult 
due to several confounding factors, including the method of size measurement and size 
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differences that occur from vial-to-vial (Shekhar et al. 2018). Due to the variation in results 
based on the method of measurement, two measuring devices were utilized to capture the 
whole range of sizes. With cooling and manual pressurization, there was often a bimodal 
distribution when sizing the particles – one containing the population of NDs and the other 
the precursor MB. In rare cases, a third peak formed in the larger range, most likely due 
to coalescence of numerous particles or large MBs. The capability to create a significant 
number of DDs < 250 nm though cooling and manual pressure shows promise for 
formulation and use of these particles at the bedside. 
In vitro testing demonstrated that DDs could be activated (vaporized) using 
settings found on a commercial US system with MIs allowed by the FDA. It was shown 
that the DDs and DMBs exhibit significantly different acoustic behavior. It was also found 
that higher concentrations of DDs compared to DMBs were required to achieve similar 
AIs. DMBs were optimally imaged with low MIs and triggered imaging; while at higher MIs, 
the particles were destroyed due to the inability to withstand the higher pressures. DDs 
required a MI of approximately 0.8 to be activated, which is most likely the point where the 
acoustic energy surpasses the Laplace pressure. Unlike DMBs, the two groups of DDs 
could be imaged at high MIs in either real-time or triggered settings. It appears that the 
DMBs that are created from the activation of DDs are able to withstand the higher acoustic 
pressures, which may be due to physical changes in the DMB shell as the chemical 
composition of the particle is unaltered. However, even these reactivated MBs were 
susceptible to destruction at the highest MI tested, though they could be imaged for a few 
frames.  
The activation of DDs was also tested in healthy swine. DMBs produced contrast 
within the LV cavity at all MIs and both imaging settings, however, myocardial contrast 
was only produced during triggered imaging. The threshold for DD activation was 
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approximately 0.7 MI. DDs produced significant contrast in the myocardium and LV cavity 
above this threshold MI in both imaging settings. Because DDs can be used to enhance 
images in real-time and at high MIs, they could be utilized in applications that MBs were 
previously not considered due to their destruction at these settings.  
The size and stability of the DDs opened up the possibility to applications within 
the extravascular space. The loss of effective cell junctions after AMI or ischemia-
reperfusion lead to the potential of using DDs to highlight the extent of the infarcted 
myocardium. We believed that the DDs may be small enough to traverse the defective 
endothelium and concentrate within the infarct zone. These particles could then be 
activated to detect and quantify infarct size. In Chapter 3, this hypothesis was tested in a 
rodent model of AMI and, subsequently, a porcine model of myocardial ischemia-
reperfusion.  
In the rodent model, confocal microscopy showed that fluorescently-tagged DDs 
were traveling across the leaky endothelium and accumulating within the infarct zone. With 
US imaging, DMBs produced contrast within the healthy myocardium as well as the LV 
cavity, and the infarcted tissue was delineated by the lack of contrast. The DMBs could 
only be imaged at low MIs for two minutes after venous administration. The DDs produced 
negligible contrast in the myocardium and LV cavity at low MIs. When the MI was 
increased two minutes after injection, there was enhancement in the LV cavity before 
persistent enhancement in the uninjured myocardium was observed. Enhancement within 
the infarct zone was observed for a few frames before the contrast defect reappeared. 
Unlike the DMBs, the DDs could be reactivated more than once to detect the infarct zone.  
The size of the infarct measured from DD enhancement correlated well with histological 
measurements. There were several limitations to the rodent model including persistent 
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enhancement in the LV cavity at the time points tested and heavy shadowing due to the 
sternum. 
To address the limitations posed by the rodent model, the imaging protocol was 
tested in a large animal model. The imaging scheme used in the porcine model was 
adjusted to optimize enhancement of the infarct zone alone. It appears that the DDs that 
accumulated within the infarct zone move slowly in random directions, while the DDs that 
remain in circulation, particularly in the LV cavity, move rapidly in the direction of blood 
flow. By utilizing a single pulse harmonic imaging sequence, only the DDs in the infarct 
zone were activated and the contrast in the LV cavity was attenuated compared to what 
was observed in the rodent model. MRI was utilized to determine the location and size of 
the infarct. There was statistically significant correlation between the infarct size measured 
from MR images and from US images.  
This initial study of the DDs demonstrated that these particles could be formulated 
at the bedside, and they could be activated and imaged using US systems currently 
utilized in the clinic. The subsequent study showed that, with further refining, delayed 
enhancement with DDs could potentially be a method of infarct detection used in clinical 
medicine. With further study of the DDs, these particles may be used in the clinic in a wide 
range of diagnostic and therapeutic applications.  
 
4.2 Future Directions 
 In this thesis, several aspects of NDs formulated from a commercially-available 
MB were studied before they were applied as an extravascular contrast agent. The studies 
presented provided critical information towards the first steps in understanding the viability 
of this ND in future clinical applications. However, before DDs can be used in humans, 
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there are several issues that need to be addressed, which include creating a protocol to 
standardize the formulation of the NDs and understanding the cavitation thresholds for the 
wide size range of NDs produced. Addressing these issues will allow for further 
development of diagnostic and therapeutic clinical applications.  
 
4.2.1 Standardization of Nanodroplet Formulation 
 The DD formulation protocol utilized in these studies was designed for simplicity – 
the DDs could be created at the bedside with minimal equipment. The DMB solution was 
loaded into either a 5 mL or 10 mL syringe attached to a high pressure stopcock before 
the syringe was placed in a cold isopropanol bath. Next, the solution was manually 
pressurized for a few minutes past the point when the solution became translucent, which 
indicates that condensation of the DMB had occurred. While this protocol produced DDs 
within the range necessary for certain applications, we have only been able to measure 
the size of DDs created under specific pressure conditions. For future studies, it will be 
important to find a method to measure the pressure applied to the DMB solution during 
condensation.   
 
4.2.2 Cavitation Measurements 
 The in vitro studies described in Chapter 2 provided some valuable insights in the 
acoustic behavior of the NDs. We were able to determine the activation threshold, and we 
found that at high MIs the DMBs formed from the reactivated DDs also undergo 
destruction. Subsequent imaging studies presented in Chapter 3 utilized DDs in a wide 
range of sizes. Thus, it is possible that the enhancement that was observed may have 
primarily been due to the activation of larger DDs. Before additional application 
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development, it will be important to determine the cavitation threshold for both the small 
and large DDs because the smaller DDs are the particles predicted to cross into the infarct 
zone. For diagnostic applications, the goal is to apply sufficient acoustic energy to activate 
(vaporize) the NDs and have them remain in stable cavitation. For therapeutic 
applications, it may be necessary for the NDs to undergo inertial cavitation. Our in vitro 
flow system can be utilized to simulate transthoracic ultrasound and determine the points 
of activation, stable cavitation, and inertial cavitation for the DDs through the use of 
passive cavitation detectors. Knowledge of the thresholds for each cavitation state will be 
a critical step moving forward.    
 
4.2.3 Future Applications  
 After the formulation protocol of the DDs is standardized and the thresholds for the 
cavitation states are determined, there are various applications (described in Table 4) 
where the DDs could be utilized, such as sonothrombolysis and drug delivery. Both of 
these applications have been studied using MBs, and the promising results described in 
thesis suggest that DDs could improve these applications.   
While several studies utilizing MBs with sonothrombolysis have been conducted 
via both in vitro and in vivo models, there have been no studies conducted using NDs with 
this application. Due to their small size, the DDs may be able to better permeate the 
thrombus and concentrate more particles within the thrombus. With activation and stable 
cavitation, the DDs may provide better thrombolysis than MBs have in the past. 
Drug delivery in the extravascular compartment using DDs may also be a potential 
application. PCA formulation through condensation of a MB precursor has eased the 
loading process as well as the tight regulation of particle size. The DDs loaded with drugs 
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Table 4. Potential nanodroplet applications. 
Diagnostic Therapeutic 
Myocardial Perfusion Sonothrombolysis 
Tumor Imaging Drug/Gene Delivery 
Molecular Imaging Oxygen Delivery 
Cardiac Imaging BBB Penetration 
Thrombus Detection Tissue Ablation 
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could be administered via the venous system before the particles are given time to 
accumulate within the targeted tissue or organ. Next, they could be activated and acoustic 
energies applied for the particles to undergo inertial cavitation to deliver the drugs locally. 
This is one of many potential ways the NDs may be able to be used for delivery.   
 
4.3 Conclusion 
The creation of PCAs has permitted several possible applications due to ND 
extravasation into the extravascular space. In this thesis, we have shown that NDs can be 
formulated from a commercially-available MB precursor, and subsequently, the PCA can 
be activated and imaged using a clinical US system. The use of PCAs for enhancing 
imaging has been one of the least explored areas, and we have demonstrated that 
delayed enhancement imaging of DDs can detect and quantify the myocardial infarction 
zone in rodent and porcine models. This new extravascular imaging method will not only 
provide critical clinical information to evaluate existing therapies, but also provide an 
imaging surrogate that can be utilized to evaluate new experimental pharmacotherapies 
and interventional techniques that are being added to the early treatment of acute 
coronary syndromes. Though substantial work remains to better understand and apply the 
NDs, the potential for the combined use of PCAs and US in the diagnosis and treatment 
of cardiovascular diseases remains promising. 
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